AU2013202593A1 - Adjuvanted vaccines for serogroup B meningococcus - Google Patents

Abstract

An immunogenic composition comprises (i) an immunostimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex, and (ii) a meningococcal serogroup B antigen. In most embodiments, the 5 composition does not include an aluminium salt and does not include an oil-in-water emulsion.

Description

ADJUVANTED VACCINES FOR SEROGROUP B MENINGOCOCCUS This application claims the benefit of US provisional patent applications 61/315,336, filed 18th March 2010, and 61/3 17,572, filed 25th March 2010, the complete contents of both of which are incorporated herein by reference for all purposes. 5 TECHNICAL FIELD This invention is in the field of meningococcal vaccines. BACKGROUNDART Various vaccines against serogroup B of Neisseria meningitidis ("MenB") are currently being investigated. Some vaccines are based on outer membrane vesicles (OMVs), such as the Novartis 10 Vaccines MENZBTM product, the Finlay Institute VA-MENGOC-BCTM product, and the Norwegian Institute of Public Health MENBVACTM product. Others are based on recombinant proteins, such as the "universal vaccine for serogroup B meningococcus" reported by Novartis Vaccines in ref. 1. It is an object of the invention to provide modified and improved vaccines against MenB and, in particular, adjuvanted vaccines. 15 DISCLOSURE OF THE INVENTION The invention provides an immunogenic composition comprising (i) a meningococcal serogroup B antigen and (ii) an adjuvant comprising an immunostimulatory oligonucleotide and a polycationic polymer; wherein (i) the immunogenic composition does not include an aluminium salt; (ii) the immunogenic composition does not include an oil-in-water emulsion; (iii) the meningococcal 20 serogroup B antigen does not include a polypeptide comprising an amino acid sequence selected from SEQ ID NOs 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and (iv) the immunogenic composition does not include a fHBP antigen. The immunostimulatory oligonucleotide and polycationic polymer preferably associate with each other. They can form an oligonucleotide/polymer complex. 25 The invention also provides an immunogenic composition comprising (i) a meningococcal serogroup B antigen; (ii) an adjuvant comprising an immunostimulatory oligonucleotide and a polycationic polymer and; (iii) one or more further antigens selected from a pneumococcal antigen, a diphtheria toxoid, tetanus toxoid, a pertussis antigen, HBsAg, a HAV antigen, a Hib antigen, and/or IPV. The immunogenic composition can also include an aluminium salt and/or an oil-in-water emulsion. 30 The invention also provides an immunogenic composition comprising (i) a purified meningococcal lipooligosaccharide; and (ii) an adjuvant comprising an immunostimulatory oligonucleotide and a polycationic polymer. The immunogenic composition can also include an aluminium salt and/ or an oil-in-water emulsion. The invention also provides an immunogenic composition comprising (i) an 5-valent antigen 35 component consisting of a MenB antigen, a conjugated capsular saccharide from serogroup A -1- N.meningitidis, a conjugated capsular saccharide from serogroup C N.meningitidis, a conjugated capsular saccharide from serogroup W135 N.meningitidis, a conjugated capsular saccharide from serogroup Y N.meningitidis; and (ii) an adjuvant comprising an immunostimulatory oligonucleotide and a polycationic polymer, provided that the immunogenic composition does not include an 5 aluminium salt and does not include an oil-in-water emulsion. In one embodiment of the invention, the MenB antigen can be adsorbed to a complex formed by the oligonucleotide and polymer in the adjuvant. Alternatively, the MenB antigen is not adsorbed to the oligonucleotide/polymer complex in the adjuvant. The invention also provides a process for preparing an immunogenic composition of the invention, 10 comprising a step of mixing (i) an adjuvant comprising a complex of an immunostimulatory oligonucleotide and a polycationic polymer and (ii) a meningococcal serogroup B ("MenB") antigen, provided that the MenB antigen does not include a polypeptide comprising an amino acid sequence selected from SEQ ID NOs 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 and does not include a fHBP antigen. In alternative methods, the MenB antigen and adjuvant comprising an immunostimulatory 15 oligonucleotide and polycationic polymer are mixed before the complex has formed. For example, the MenB antigen can be mixed with the oligonucleotide, and then the polymer is added; or the MenB antigen can be mixed with the polymer, and then the oligonucleotide is added. The complex may form after the oligonucleotide and the polymer meet. The MenB antigen, oligonucleotide and polymer may be mixed in any order. 20 The invention also provides a kit comprising: (i) a first container that contains an immunostimulatory oligonucleotide and a polycationic polymer and (ii) a second container that contains a MenB antigen provided that the MenB antigen does not include a polypeptide comprising an amino acid sequence selected from SEQ ID NOs 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 and does not include a fHBP antigen Neither the first container nor the second container in the kit includes an aluminium salt or an 25 oil-in-water emulsion. The invention also provides a kit comprising (i) a first container that contains an immunostimulatory oligonucleotide and a polycationic polymer and (ii) a second container that contains a purified meningococcal lipooligosaccharide. The invention also provides a kit comprising which comprises (i) a first container that contains an 30 immunostimulatory oligonucleotide and a polycationic polymer and (ii) a second container that contains a meningococcal serogroup B antigen and (iii) a container that contains one or more further antigens selected from a pneumococcal antigen, diphtheria toxoid, tetanus toxoid, a pertussis antigen, HBsAg, a HAV antigen, Hib antigen, and/or IPV. The container mentioned in part (iii) can be the first container, the second container, or a third container. -2- The contents of the containers in these kits can be combined (e.g. at the point of use) to form an immunogenic composition of the invention. These kits may include a further container that contains an immunogen and/or a further adjuvant. In some embodiments, the only adjuvant in a composition or kit is the adjuvant comprising an 5 immunostimulatory oligonucleotide and a polycationic polymer. Serogroup B meningococcus immunogens Immunogenic compositions of the invention are useful for eliciting an immune response against serogroup B meningococcus ("MenB"). Suitable immunogens for eliciting anti-MenB responses include polypeptide antigens, lipooligosaccharide and/or membrane vesicles. Further details of useful 10 serogroup B antigens are given below. Meningococcal polypeptide antigens An immunogenic composition of the invention may include one or more meningococcal polypeptide antigen(s). For instance, a composition may include a polypeptide antigen selected from the group consisting of: 287, NadA, NspA, HmbR, NhhA, App and/or Omp85. These antigens will usefully be 15 present as purified polypeptides e.g. recombinant polypeptides. The antigen will preferably elicit bactericidal anti-meningococcal antibodies after administration to a subject. An immunogenic composition of the invention may include a 287 antigen. The 287 antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [2] as gene NMB2132 (GenBank accession number GI:7227388; SEQ ID NO: 3 herein). The sequences of 287 20 antigen from many strains have been published since then. For example, allelic forms of 287 can be seen in Figures 5 and 15 of reference 3, and in example 13 and figure 21 of reference 4 (SEQ IDs 3179 to 3184 therein). Various immunogenic fragments of the 287 antigen have also been reported. Preferred 287 antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 25 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 3; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 3, wherein 'n' is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 3. The most useful 287 antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino 30 acid sequence SEQ ID NO: 3. Advantageous 287 antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject. An immunogenic composition of the invention composition of the invention may include a NadA antigen. The NadA antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [2] as gene NMB1994 (GenBank accession number GI:7227256; SEQ ID 35 NO: 4 herein). The sequences of NadA antigen from many strains have been published since then, and the protein's activity as a Neisserial adhesin has been well documented. Various immunogenic -3fragments of NadA have also been reported. Preferred NadA antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 4; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 4, wherein 'n' 5 is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 4. SEQ ID NO: 6 is one such fragment. The most useful NadA antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 4. Advantageous NadA antigens for use with the invention can elicit 10 bactericidal anti-meningococcal antibodies after administration to a subject. An immunogenic composition of the invention may include a NspA antigen. The NspA antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [2] as gene NMB0663 (GenBank accession number GI:7225888; SEQ ID NO: 5 herein). The antigen was previously known from references 5 & 6. The sequences of NspA antigen from many strains have 15 been published since then. Various immunogenic fragments of NspA have also been reported. Preferred NspA antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 5; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 5, wherein 'n' is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 5. The most useful NspA antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 5. Advantageous NspA antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject. 25 An immunogenic composition of the invention may include a meningococcal HmbR antigen. The full-length HmbR sequence was included in the published genome sequence for meningococcal serogroup B strain MC58 [2] as gene NMB1668 (SEQ ID NO: 12 herein). The invention can use a polypeptide that comprises a full-length HmbR sequence, but it will often use a polypeptide that comprises a partial HmbR sequence. Thus in some embodiments a HmbR sequence used according 30 to the invention may comprise an amino acid sequence having at least i% sequence identity to SEQ ID NO: 12, where the value of i is 50, 60, 70, 80, 90, 95, 99 or more. In other embodiments a HmbR sequence used according to the invention may comprise a fragment of at least j consecutive amino acids from SEQ ID NO: 12, where the value of j is 7, 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more. In other embodiments a HmbR sequence used according to 35 the invention may comprise an amino acid sequence (i) having at least i% sequence identity to SEQ ID NO: 12 and/or (ii) comprising a fragment of at least j consecutive amino acids from SEQ ID NO: 12. Preferred fragments of j amino acids comprise an epitope from SEQ ID NO: 12. Such epitopes will usually comprise amino acids that are located on the surface of HmbR. Useful epitopes include -4those with amino acids involved in HmbR's binding to haemoglobin, as antibodies that bind to these epitopes can block the ability of a bacterium to bind to host haemoglobin. The topology of HmbR, and its critical functional residues, were investigated in reference 7. The most useful HmbR antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a 5 meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 12. Advantageous HmbR antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject. An immunogenic composition of the invention may include a NhhA antigen. The NhhA antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [2] as gene 10 NMB0992 (GenBank accession number GI:7226232; SEQ ID NO: 6 herein). The sequences of NhhA antigen from many strains have been published since e.g. refs 3 & 8, and various immunogenic fragments of NhhA have been reported. It is also known as Hsf. Preferred NhhA antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 15 99%, 99.5% or more) to SEQ ID NO: 6; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 6, wherein 'n' is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 6. The most useful NhhA antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid 20 sequence SEQ ID NO: 6. Advantageous NhhA antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject. An immunogenic composition of the invention may include an App antigen. The App antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [2] as gene NMB1985 (GenBank accession number GI:7227246; SEQ ID NO: 7 herein). The sequences of App 25 antigen from many strains have been published since then. Various immunogenic fragments of App have also been reported. Preferred App antigens for use with the invention comprise an amino acid sequence: (a) having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 7; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 7, wherein 'n' is 7 or more (e.g. 8, 10, 30 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 7. The most useful App antigens of the invention can elicit antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 7. Advantageous App antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a 35 subject. An immunogenic composition of the invention may include an Omp85 antigen. The Omp85 antigen was included in the published genome sequence for meningococcal serogroup B strain MC58 [2] as -5gene NMB0182 (GenBank accession number GI:7225401; SEQ ID NO: 8 herein). The sequences of Omp85 antigen from many strains have been published since then. Further information on Omp85 can be found in references 9 and 10. Various immunogenic fragments of Omp85 have also been reported. Preferred Omp85 antigens for use with the invention comprise an amino acid sequence: (a) 5 having 50% or more identity (e.g. 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 8; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 8, wherein 'n' is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). Preferred fragments of (b) comprise an epitope from SEQ ID NO: 8. The most useful Omp85 antigens of the invention can elicit 10 antibodies which, after administration to a subject, can bind to a meningococcal polypeptide consisting of amino acid sequence SEQ ID NO: 8. Advantageous Omp85 antigens for use with the invention can elicit bactericidal anti-meningococcal antibodies after administration to a subject. Compositions of the invention do not include meningococcal factor H binding protein (fHBP) antigen. A fHBP antigen is a polypeptide comprising an amino acid sequence, (i) having at least 80% 15 sequence identity to any one of SEQ ID NOs: 9, 10, or 11 and/or (ii) consisting of a fragment of at least 7 contiguous amino acids from SEQ ID NOs: 9, 10 or 11. In some embodiments the compositions do not include a protein which can bind to factor H (e.g. human factor H) in an assay as described in references 11 and 12. Fragments preferably comprise an epitope from the respective SEQ ID NO: sequence. Other useful 20 fragments lack one or more amino acids (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the C-terminus and/or one or more amino acids (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the N-terminus of the respective SEQ ID NO: while retaining at least one epitope thereof. In some embodiments polypeptide(s) are lipidated e.g. at a N-terminus cysteine. For lipidated polypeptide(s), lipids attached to cysteines will usually include palmitoyl residues e.g. as 25 tripalmitoyl-S-glyceryl-cysteine (Pam3Cys), dipalmitoyl-S-glyceryl cysteine (Pam2Cys), N-acetyl (dipalmitoyl-S-glyceryl cysteine), etc. Meningococcal lipooligosaccharide An immunogenic composition may include one or more meningococcal lipooligosaccharide (LOS) antigen(s). Meningococcal LOS is a glucosamine-based phospholipid that is found in the outer 30 monolayer of the outer membrane of the bacterium. It includes a lipid A portion and a core oligosaccharide region, with the lipid A portion acting as a hydrophobic anchor in the membrane. Heterogeneity within the oligosaccharide core generates structural and antigenic diversity among different meningococcal strains, which has been used to subdivide the strains into 12 immunotypes (LI to L12). The invention may use LOS from any immunotype e.g. from L1, L2, L3, L4, L5, L6, L7 35 and/or L8. The L2 and L3 a-chains naturally include lacto-N-neotetraose (LNnT). Where the invention uses LOS from a L2 or L3 immunotype this LNnT may be absent. This absence can be achieved -6conveniently by using mutant strains that are engineered to disrupt their ability to synthesise the LNnT tetrasaccharide within the a-chain. It is known to achieve this goal by knockout of the enzymes that are responsible for the relevant biosynthetic additions [13,43]. For instance, knockout of the LgtB enzyme prevents addition of the terminal galactose of LNnT, as well as preventing 5 downstream addition of the a-chain's terminal sialic acid. Knockout of the LgtA enzyme prevents addition of the N-acetyl-glucosamine of LNnT, and also the downstream additions. LgtA knockout may be accompanied by LgtC knockout. Similarly, knockout of the LgtE and/or GalE enzyme prevents addition of internal galactose, and knockout of LgtF prevents addition of glucose to the Hepi residue. Any of these knockouts can be used, singly or in combination, to disrupt the LNnT 10 tetrasaccharide in a L2, L3, L4, L7 or L9 immunotype strain. Knockout of at least LgtB is preferred, as this provides a LOS that retains useful immunogenicity while removing the LNnT epitope. In addition to, or in place of, mutations to disrupt the LNnT epitope, a knockout of the galE gene also provides a useful modified LOS, and a lipid A fatty transferase gene may similarly be knocked out [14]. At least one primary 0-linked fatty acid may be removed from LOS [15]. LOS having a 15 reduced number of secondary acyl chains per LOS molecule can also be used [16].The LOS will typically include at least the GlcNAc-Hep 2 phosphoethanolamine-KDO 2 -Lipid A structure [17]. The LOS may include a GlcNAcp1-3Galp1-4Glc trisaccharide while lacking the LNnT tetrasaccharide. LOS may be included in various forms. It may be used in purified form on its own. It may be conjugated to a carrier protein. When LOS is conjugated, conjugation may be via a lipid A portion in 20 the LOS or by any other suitable moiety e.g. its KDO residues. If the lipid A moiety of LOS is absent then such alternative linking is required. Conjugation techniques for LOS are known from e.g. references 15, 17, 18, 19, etc. Useful carrier proteins for these conjugates include e.g. bacterial toxins, such as diphtheria or tetanus toxins, or toxoids or mutants thereof. The LOS may be from a strain (e.g. a genetically-engineered meningococcal strain) which has a 25 fixed (i.e. not phase variable) LOS immunotype as described in reference 20. For example, L2 and L3 LOS immunotypes may be fixed. Such strains may have a rate of switching between immunotypes that is reduced by more than 2-fold (even >50_fold) relative to the original wild-type strain. Reference 20 discloses how this result can be achieved by modification of the lgtA and/or lgtG gene products. 30 LOS may be O-acetylated on a GlcNac residue attached to its Heptose II residue e.g. for L3 [21]. An immunogenic composition of the invention can include more than one type of LOS e.g. LOS from meningococcal immunotypes L2 and L3. For example, the LOS combinations disclosed in reference 22 may be used. A LOS antigen can preferably elicit bactericidal anti-meningococcal antibodies after administration 35 to a subject. -7- Membrane vesicles An immunogenic composition of the invention may include meningococcal outer membrane vesicles. These include any proteoliposomic vesicle obtained by disruption of or blebbling from a meningococcal outer membrane to form vesicles therefrom that include protein components of the 5 outer membrane. Thus the term includes OMVs (sometimes referred to as 'blebs'), microvesicles (MVs [23]) and 'native OMVs' ('NOMVs' [24]). MVs and NOMVs are naturally-occurring membrane vesicles that form spontaneously during bacterial growth and are released into culture medium. MVs can be obtained by culturing Neisseria in broth culture medium, separating whole cells from the smaller MVs in the broth culture medium 10 (e.g. by filtration or by low-speed centrifugation to pellet only the cells and not the smaller vesicles), and then collecting the MVs from the cell-depleted medium (e.g. by filtration, by differential precipitation or aggregation of MVs, by high-speed centrifugation to pellet the MVs). Strains for use in production of MVs can generally be selected on the basis of the amount of MVs produced in culture e.g. refs. 25 & 26 describe Neisseria with high MV production. 15 OMVs are prepared artificially from bacteria, and may be prepared using detergent treatment (e.g. with deoxycholate), or by non-detergent means (e.g. see reference 27). Techniques for forming OMVs include treating bacteria with a bile acid salt detergent (e.g. salts of lithocholic acid, chenodeoxycholic acid, ursodeoxycholic acid, deoxycholic acid, cholic acid, ursocholic acid, etc., with sodium deoxycholate [28 & 29] being preferred for treating Neisseria) at a pH sufficiently high 20 not to precipitate the detergent [30]. Other techniques may be performed substantially in the absence of detergent [27] using techniques such as sonication, homogenisation, microfluidisation, cavitation, osmotic shock, grinding, French press, blending, etc. Methods using no or low detergent can retain useful antigens such as NspA [27]. Thus a method may use an OMV extraction buffer with about 0.5% deoxycholate or lower e.g. about 0.2%, about 0.1%, <0.05% or zero. 25 A useful process for OMV preparation is described in reference 31 and involves ultrafiltration on crude OMVs, rather than instead of high speed centrifugation. The process may involve a step of ultracentrifugation after the ultrafiltration takes place. Vesicles for use with the invention can be prepared from any meningococcal strain. The vesicles will usually be from a serogroup B strain, but it is possible to prepare them from serogroups other than B 30 (e.g. reference 30 discloses a process for serogroup A), such as A, C, W135 or Y. The strain may be of any serotype (e.g. 1, 2a, 2b, 4, 14, 15, 16, etc.), any serosubtype, and any immunotype (e.g. Li; L2; L3; L3,3,7; L1O; etc.). The meningococci may be from any suitable lineage, including hyperinvasive and hypervirulent lineages e.g. any of the following seven hypervirulent lineages: subgroup I; subgroup III; subgroup IV-1; ET-5 complex; ET-37 complex; A4 cluster; lineage 3. 35 These lineages have been defined by multilocus enzyme electrophoresis (MLEE), but multilocus sequence typing (MLST) has also been used to classify meningococci [ref. 32] e.g. the ET-37 complex is the ST-1I complex by MLST, the ET-5 complex is ST-32 (ET-5), lineage 3 is ST-41/44, -8etc. Vesicles can be prepared from strains having one of the following subtypes: P1.2; P1.2,5; P1.4; P1.5; P1.5,2; P1.5,c; P1.5c,10; P1.7,16; P1.7,16b; P1.7h,4; P1.9; P1.15; P1.9,15; P1.12,13; P1.13; P1.14; P1.21,16; P1.22,14. Vesicles used with the invention may be prepared from wild-type meningococcal strains or from 5 mutant meningococcal strains. For instance, reference 33 discloses preparations of vesicles obtained from N.meningitidis with a modifiedfur gene. Reference 41 teaches that nspA expression should be up-regulated with concomitant porA and cps knockout. Further knockout mutants of N.meningitidis for OMV production are disclosed in references 41 to 43. Reference 34 discloses vesicles in which fHBP is upregulated. Reference 35 discloses the construction of vesicles from strains modified to 10 express six different PorA subtypes. Mutant Neisseria with low endotoxin levels, achieved by knockout of enzymes involved in LPS biosynthesis, may also be used [36,37]. These or others mutants can all be used with the invention. Thus a strain used with the invention may in some embodiments express more than one PorA subtype. 6-valent and 9-valent PorA strains have previously been constructed. The strain may 15 express 2, 3, 4, 5, 6, 7, 8 or 9 of PorA subtypes: P1.7,16; P1.5-1,2-2; P1.19,15-1; P1.5-2,10; P1.12-1,13; P1.7-2,4; P1.22,14; P1.7-1,1 and/or P1.18-1,3,6. In other embodiments a strain may have been down-regulated for PorA expression e.g. in which the amount of PorA has been reduced by at least 20% (e.g. >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, etc.), or even knocked out, relative to wild-type levels (e.g. relative to strain H44/76, as disclosed in reference 44). 20 In some embodiments a strain may hyper-express (relative to the corresponding wild-type strain) certain proteins. For instance, strains may hyper-express NspA, protein 287 [38], fHBP [34], TbpA and/or TbpB [39], Cu,Zn-superoxide dismutase [39], HmbR, etc. In some embodiments a strain may include one or more of the knockout and/or hyper-expression mutations disclosed in references 40 to 43. Preferred genes for down-regulation and/or knockout 25 include: (a) Cps, CtrA, CtrB, CtrC, CtrD, FrpB, GalE, HtrB/MsbB, LbpA, LbpB, LpxK, Opa, Opc, PilC, PorB, SiaA, SiaB, SiaC, SiaD, TbpA, and/or TbpB [40]; (b) CtrA, CtrB, CtrC, CtrD, FrpB, GalE, HtrB/MsbB, LbpA, LbpB, LpxK, Opa, Opc, PhoP, PilC, PmrE, PmrF, SiaA, SiaB, SiaC, SiaD, TbpA, and/or TbpB [41]; (c) ExbB, ExbD, rmpM, CtrA, CtrB, CtrD, GalE, LbpA, LpbB, Opa, Opc, PilC, PorB, SiaA, SiaB, SiaC, SiaD, ThpA, and/or TbpB [42]; and (d) CtrA, CtrB, CtrD, FrpB, OpA, 30 OpC, PilC, PorB, SiaD, SynA, SynB, and/or SynC [43]. Where a mutant strain is used, in some embodiments it may have one or more, or all, of the following characteristics: (i) down-regulated or knocked-out LgtB and/or GalE to truncate the meningococcal LOS; (ii) up-regulated TbpA; (iii) up-regulated NhhA; (iv) up-regulated Omp85; (v) up-regulated LbpA; (vi) up-regulated NspA; (vii) knocked-out PorA; (viii) down-regulated or knocked-out FrpB; 35 (ix) down-regulated or knocked-out Opa; (x) down-regulated or knocked-out Opc; (xii) deleted cps gene complex. A truncated LOS can be one that does not include a sialyl-lacto-N-neotetraose epitope e.g. it might be a galactose-deficient LOS. The LOS may have no a chain. -9- If LOS is present in a vesicle it is possible to treat the vesicle so as to link its LOS and protein components ("intra-bleb" conjugation [43]). The invention may be used with mixtures of vesicles from different strains. For instance, reference 44 discloses vaccine comprising multivalent meningococcal vesicle compositions, comprising a first 5 vesicle derived from a meningococcal strain with a serosubtype prevalent in a country of use, and a second vesicle derived from a strain that need not have a serosubtype present in a country of use. Reference 45 also discloses useful combinations of different vesicles. A combination of vesicles from strains in each of the L2 and L3 immunotypes may be used in some embodiments. In some embodiments, the immunogenic composition does not contain MenB OMV. 10 Immunogenic compositions of the invention can be administered to animals to induce an immune response. The invention can be used for treating or protecting against a wide range of diseases. The immunostimulatory oligonucleotide and the polycationic polymer The invention uses an immunostimulatory oligonucleotide and a polycationic polymer. These are ideally associated with each other to form a particulate complex, which usefully is a TLR9 agonist. 15 Immunostimulatory oligonucleotides are known as useful adjuvants. They often contain a CpG motif (a dinucleotide sequence containing an unmethylated cytosine linked to a guanosine) and their adjuvant effect is discussed in refs. 46-51. Oligonucleotides containing TpG motifs, palindromic sequences, multiple consecutive thymidine nucleotides (e.g. TTTT), multiple consecutive cytosine nucleotides (e.g. CCCC) or poly(dG) sequences are also known immunostimulants, as are 20 double-stranded RNAs. Although any of these various immunostimulatory oligonucleotides can be used with the invention, it is preferred to use an oligodeoxynucleotide containing deoxyinosine and/or deoxyuridine [52], and ideally an oligodeoxynucleotide containing deoxyinosine and deoxycytosine. Inosine-containing oligodeoxynucleotides may include a CpI motif (a dinucleotide sequence containing a cytosine linked to an inosine). The oligodeoxynucleotide may include more 25 than one (e.g. 2, 3, 4, 5, 6 or more) CpI motif, and these may be directly repeated (e.g. comprising the sequence (CI),, where x is 2, 3, 4, 5, 6 or more) or separated from each other (e.g. comprising the sequence (CIN)X, where x is 2, 3, 4, 5, 6 or more, and where each N independently represents one or more nucleotides). Cytosine residues are ideally unmethylated. The oligonucleotides will typically have between 10 and 100 nucleotides e.g. 15-50 nucleotides, 30 20-30 nucleotides, or 25-28 nucleotides. It will typically be single-stranded. The oligonucleotide can include exclusively natural nucleotides, exclusively non-natural nucleotides, or a mix of both. For instance, it may include one or more phosphorothioate linkage(s), and/or one or more nucleotides may have a 2'-O-methyl modification. -10- A preferred oligonucleotide for use with the invention is a single-stranded deoxynucleotide comprising the 26-mer sequence 5'-(IC) 13 -3' (SEQ ID NO: 1). This oligodeoxynucleotide forms stable complexes with polycationic polymers to give a good adjuvant. The polycationic polymer is ideally a polycationic peptide, such as a cationic antimicrobial peptide. 5 The polymer may include one or more leucine amino acid residue(s) and/or one or more lysine amino acid residue(s). The polymer may include one or more arginine amino acid residue(s). It may include at least one direct repeat of one of these amino acids e.g. one or more Leu-Leu dipeptide sequence(s), one or more Lys-Lys dipeptide sequence(s), or one or more Arg-Arg dipeptide sequence(s). It may include at least one (and preferably multiple e.g. 2 or 3) Lys-Leu dipeptide sequence(s) and/or at 10 least one (and preferably multiple e.g. 2 or 3) Lys-Leu-Lys tripeptide sequence(s). The peptide may comprise a sequence R-XZXZXZX-R 2 , wherein: x is 3, 4, 5, 6 or 7; each X is independently a positively-charged natural and/or non-natural amino acid residue; each Z is independently an amino acid residue L, V, I, F or W; and R 1 and R 2 are independently selected from the group consisting of -H, -NH 2 , -COCH 3 , or -COH. In some embodiments X-R 2 may be an amide, 15 ester or thioester of the peptide's C-terminal amino acid residue. See also reference 53. A polycationic peptide will typically have between 5 and 50 amino acids e.g. 6-20 amino acids, 7-15 amino acids, or 9-12 amino acids. A peptide can include exclusively natural amino acids, exclusively non-natural amino acids, or a mix of both. It may include L-amino acids and/or D-amino acids. L-amino acids are typical. 20 A peptide can have a natural N-terminus (NH 2 -) or a modified N-terminus e.g. a hydroxyl, acetyl, etc. A peptide can have a natural C-terminus (-COOH) or a modified C-terminus e.g. a hydroxyl, an acetyl, etc. Such modifications can improve the peptide's stability. A preferred peptide for use with the invention is the I-mer KLKLLLLLKLK (SEQ ID NO: 2; ref. 54), with all L-amino acids. The N-terminus may be deaminated and the C-terminus may be 25 hydroxylated. A preferred peptide is H-KLKL 5 KLK-OH, with all L-amino acids. This oligopeptide is a known antimicrobial [55], neutrophil activator [56] and adjuvant [57] and forms stable complexes with immunostimulatory oligonucleotides to give a good adjuvant. The most preferred mixture of immunostimulatory oligonucleotide and polycationic polymer is the TLR9 agonist known as IC31TM [58-60], which is an adsorptive complex of oligodeoxynucleotide 30 SEQ ID NO: 1 and polycationic oligopeptide SEQ ID NO: 2. The oligonucleotide and oligopeptide can be mixed together at various ratios, but they will generally be mixed with the peptide at a molar excess. The molar excess may be at least 5:1 e.g. 10:1, 15:1, 20:1, 25:1, 30;1, 35:1, 40:1 etc. A molar ratio of about 25:1 is ideal [61,62]. Mixing at this excess ratio can result in formation of insoluble particulate complexes between oligonucleotide and 35 oligopeptide. Where the MenB antigen is purified LOS, the complexes can be combined with an aluminium salt as described herein. -11- The oligonucleotide and oligopeptide will typically be mixed under aqueous conditions e.g. a solution of the oligonucleotide can be mixed with a solution of the oligopeptide with a desired ratio. The two solutions may be prepared by dissolving dried (e.g. lyophilised) materials in water or buffer to form stock solutions that can then be mixed. 5 The complexes can be analysed using the methods disclosed in reference 63. Complexes with an average diameter in the range 1pm-20pm are typical. Poly-arginine and CpG oligodeoxynucleotides similarly form complexes [64]. The complexes can be maintained in aqueous suspension e.g. in water or in buffer. Typical buffers for use with the complexes are phosphate buffers (e.g. phosphate-buffered saline), Tris buffers, 10 Tris/sorbitol buffers, borate buffers, succinate buffers, citrate buffers, histidine buffers, etc. As an alternative, complexes may sometimes be lyophilised. Complexes in aqueous suspension can be centrifuged to separate them from bulk medium (e.g. by aspiration, decanting, etc.). These complexes can then be re-suspended in an alternative medium if desired. 15 Aluminium salts Most embodiments of the invention do not include an aluminium salt. Some embodiments permit the use of aluminium salts, however; for example, where the immunogenic composition comprises a purified MenB LOS or where the composition includes one or more further antigens selected from pneumococcal saccharide antigen, diphtheria toxoid, tetanus toxoid, pertussis antigen, HBsAg, HAV 20 antigen, Hib antigen and IPV. Aluminium salts include the adjuvants known individually as aluminium hydroxide and aluminium phosphate. These names are conventional, but are used for convenience only, as neither is a precise description of the actual chemical compound which is present [e.g. see chapter 9 of reference 65]. The term "aluminium salt" also refers to any of the "hydroxide" or "phosphate" adjuvants that are in general use as adjuvants. In some embodiments, 25 which permit aluminium salts, the use of an aluminium hydroxide adjuvant is preferred. The adjuvants known as "aluminium hydroxide" are typically aluminium oxyhydroxide salts, which are usually at least partially crystalline. Aluminium oxyhydroxide, which can be represented by the formula A1O(OH), can be distinguished from other aluminium compounds, such as aluminium hydroxide Al(OH) 3 , by infrared (IR) spectroscopy, in particular by the presence of an adsorption 30 band at 1070cm- 1 and a strong shoulder at 3090-3100cm- 1 [chapter 9 of ref. 65]. The degree of crystallinity of an aluminium hydroxide adjuvant is reflected by the width of the diffraction band at half height (WHH), with poorly-crystalline particles showing greater line broadening due to smaller crystallite sizes. The surface area increases as WHH increases, and adjuvants with higher WHH values have been seen to have greater capacity for antigen adsorption. A fibrous morphology (e.g. as 35 seen in transmission electron micrographs) is typical for aluminium hydroxide adjuvants. Mean particle diameters in the range of 1-10pm are reported in reference 66. The pI of aluminium -12hydroxide adjuvants is typically about 11 i.e. the adjuvant itself has a positive surface charge at physiological pH. Adsorptive capacities of between 1.8-2.6 mg protein per mg Al.** at pH 7.4 have been reported for aluminium hydroxide adjuvants. The adjuvants known as "aluminium phosphate" are typically aluminium hydroxyphosphates, often 5 also containing a small amount of sulfate (i.e. aluminium hydroxyphosphate sulfate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt. Hydroxyphosphates generally have a PO 4 /Al molar ratio between 0.3 and 1.2. Hydroxyphosphates can be distinguished from strict AlPO 4 by the presence of hydroxyl groups. For example, an IR spectrum band at 10 3164cm- 1 (e.g. when heated to 200'C) indicates the presence of structural hydroxyls [chapter 9 of ref. 65]. The PO 4 /A13+ molar ratio of an aluminium phosphate adjuvant will generally be between 0.3 and 1.2, preferably between 0.8 and 1.2, and more preferably 0.95+0.1. The aluminium phosphate will generally be amorphous, particularly for hydroxyphosphate salts. A typical adjuvant is amorphous aluminium hydroxyphosphate with PO 4 /Al molar ratio between 0.84 and 0.92, included 15 at 0.6mg A3/ml. The aluminium phosphate will generally be particulate (e.g. plate-like morphology as seen in transmission electron micrographs). Typical diameters of the particles are in the range 0.5 20pm (e.g. about 5-10pm) after any antigen adsorption. Adsorptive capacities of between 0.7-1.5 mg protein per mg Al.** at pH 7.4 have been reported for aluminium phosphate adjuvants. The point of zero charge (PZC) of aluminium phosphate is inversely related to the degree of substitution of 20 phosphate for hydroxyl, and this degree of substitution can vary depending on reaction conditions and concentration of reactants used for preparing the salt by precipitation. PZC is also altered by changing the concentration of free phosphate ions in solution (more phosphate = more acidic PZC) or by adding a buffer such as a histidine buffer (makes PZC more basic). Aluminium phosphates used according to the invention will generally have a PZC of between 4.0 and 7.0, more preferably 25 between 5.0 and 6.5 e.g. about 5.7. A mixture of both an aluminium hydroxide and an aluminium phosphate has can also be used. In this situation there may be more aluminium phosphate than hydroxide e.g. a weight ratio of at least 2:1 e.g. >5:1, >6:1, >7:1, >8:1, >9:1, etc. In some embodiments of the invention (e.g. wherein the immunogenic composition comprises a 30 purified MenB LOS) the composition may comprise: (i) an aluminium hydroxide, an immunostimulatory oligonucleotide and a polycationic polymer; (ii) an aluminium phosphate, an immunostimulatory oligonucleotide and a polycationic polymer; or (iii) an aluminium hydroxide, an aluminium phosphate, an immunostimulatory oligonucleotide and a polycationic polymer. The concentration of Al.** in a pharmaceutical composition of the invention will usually be 35 <10mg/ml e.g. 5 mg/ml, <4 mg/ml, <3 mg/ml, <2 mg/ml, <1 mg/ml, etc. A preferred range is between 0.3 and 1mg/mil. -13- Adsorption Preferred complexes of immunostimulatory oligonucleotide and polycationic polymer are adsorptive i.e. immunogens can adsorb to the complexes, by a variety of mechanisms. In some circumstances, however, immunogen and complex can both be present in a composition without adsorption, either 5 through an intrinsic property of the immunogen or because of steps taken during formulation (e.g. the use of an appropriate pH during formulation to prevent adsorption from occurring). Aluminium salt adjuvants are also adsorptive. In embodiments where a complex and an aluminium salt are both present, therefore, there can be multiple adsorptive opportunities for an immunogen: an immunogen can adsorb to aluminium salt, to a oligonucleotide/polymer complex, to both (in various 10 proportions), or to neither. The invention covers all such arrangements. For example, in one embodiment an immunogen can be adsorbed to an aluminium salt, and the adsorbed immunogen/salt can then be mixed with an oligonucleotide/polymer complex. In another embodiment an immunogen can be adsorbed to an oligonucleotide/polymer complex, and the adsorbed immunogen/complex can then be mixed with an aluminium salt. In another embodiment two immunogens (the same or 15 different) can be separately adsorbed to an oligonucleotide/polymer complex and to an aluminium salt, and the two adsorbed components can then be mixed. In some situations, an immunogen may change its adsorption status e.g. by a change in pH or temperature, or after mixing of components. Desorption of antigens from aluminium salts in vitro [67] and in vivo [68] is known. Desorption from one adsorptive particle followed by resorption to a 20 different adsorptive particle can occur, thereby resulting in e.g. transfer of an immunogen from an aluminium salt adjuvant to a complex or vice versa. In some embodiments, a single antigen molecule or complex might adsorb to both an aluminium salt and a complex, forming a bridge between the two adsorptive particles. If an immunogen adsorbs to an adsorptive component, it is not necessary for all of the immunogen to 25 adsorb. This situation can occur because of an immunogen's intrinsic equilibrium between adsorbed and soluble phases, or because adsorptive surfaces are saturated. Thus the immunogen in a composition may be fully or partially adsorbed, and the adsorbed fraction can be on one or more different adsorptive components (e.g. on aluminium salt and/or on a oligonucleotide/polymer complex). In this situation, the adsorbed fraction may be at least 10% (by weight) of the total amount 30 of that immunogen in the composition e.g. >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98% or more. In some embodiments an immunogen is totally adsorbed i.e. none is detectable in the supernatant after centrifugation to separate complexes from bulk liquid medium. In other embodiments, though, none of a particular immunogen may be adsorbed. In some circumstances it is possible that the immunostimulatory oligonucleotide and/or polycationic 35 polymer component of a complex could adsorb to an aluminium salt. Preferably, though, the complexes remain intact after mixing with an aluminium salt. Also, to avoid adsorption of complexes to an aluminium salt (and vice versa) it is useful that the aluminium salt and the complexes have -14similar points of zero charge (isoelectric points) e.g. within 1 pH unit of each other. Thus useful complexes have a PZC of between 10 and 12, which is useful for combining with an aluminium hydroxide adjuvant having a PZC of about 11. The oil-in-water emulsion 5 Most embodiments do not contain an "oil-in-water" emulsion, although some embodiments permit their presence e.g. where the immunogenic composition comprises a purified MenB LOS Oil-in water emulsions typically include at least one surfactant, with the oil(s) and surfactant(s) being biodegradable (metabolisable) and biocompatible. The oil droplets in the emulsion are generally less than 5pm in diameter, and ideally have a 10 sub-micron diameter, with these small sizes being achieved with a microfluidiser to provide stable emulsions. Droplets with a size less than 220nm are preferred as they can be subjected to filter sterilization. In some useful emulsions at least 80% (by number) of the oil droplets have a diameter less than 500nm. The emulsions can include oils such as those from an animal (such as fish) or vegetable source. 15 Sources for vegetable oils include nuts, seeds and grains. Peanut oil, soybean oil, coconut oil, and olive oil, the most commonly available, exemplify the nut oils. Jojoba oil can be used e.g. obtained from the jojoba bean. Seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil, etc. In the grain group, corn oil is the most readily available, but the oil of other cereal grains such as wheat, oats, rye, rice, teff, triticale, etc. may also be used. 6-10 carbon fatty acid esters of 20 glycerol and 1,2-propanediol, while not occurring naturally in seed oils, may be prepared by hydrolysis, separation and esterification of the appropriate materials starting from the nut and seed oils. Fats and oils from mammalian milk are metabolizable and may therefore be used in the practice of this invention. The procedures for separation, purification, saponification and other means necessary for obtaining pure oils from animal sources are well known in the art. Most fish contain 25 metabolizable oils which may be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti exemplify several of the fish oils which may be used herein. A number of branched chain oils are synthesized biochemically in 5-carbon isoprene units and are generally referred to as terpenoids. Shark liver oil contains a branched, unsaturated terpenoid known as squalene, 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene. Squalane, the saturated 30 analog to squalene, can also be used. Fish oils, including squalene and squalane, are readily available from commercial sources or may be obtained by methods known in the art. Squalene is preferred. Other useful oils are the tocopherols, which are advantageously included in vaccines for use in elderly subjects (e.g. aged 60 years or older) because vitamin E has been reported to have a positive effect on the immune response in this subject group. They also have antioxidant properties that may 35 help to stabilize emulsions. Various tocopherols exist (a, P, y, 5, E or ) but a is usually used. A preferred a-tocopherol is DL-a-tocopherol. a-tocopherol succinate is known to be compatible with influenza vaccines and to be a useful preservative as an alternative to mercurial compounds. -15- Mixtures of oils can be used e.g. squalene and a-tocopherol. An oil content in the range of 2-20% (by volume) is typical. Surfactants can be classified by their 'HLB' (hydrophile/lipophile balance). Some surfactants useful with the invention have a HLB of at least 10 e.g. at least 15 or at least 16. The invention can be used 5 with surfactants including, but not limited to: the polyoxyethylene sorbitan esters surfactants (commonly referred to as the Tweens), especially polysorbate 20 and polysorbate 80; copolymers of ethylene oxide (EO), propylene oxide (PO), and/or butylene oxide (BO), sold under the DOWFAXTM tradename, such as linear EO/PO block copolymers; octoxynols, which can vary in the number of repeating ethoxy (oxy-1,2-ethanediyl) groups, with octoxynol-9 (Triton X-100, or 10 t-octylphenoxypolyethoxyethanol) being of particular interest; (octylphenoxy)polyethoxyethanol (IGEPAL CA-630/NP-40); phospholipids such as phosphatidylcholine (lecithin); nonylphenol ethoxylates, such as the TergitolTM NP series; polyoxyethylene fatty ethers derived from lauryl, cetyl, stearyl and oleyl alcohols (known as Brij surfactants), such as triethyleneglycol monolauryl ether (Brij 30); and sorbitan esters (commonly known as the SPANs), such as sorbitan trioleate (Span 85) 15 and sorbitan monolaurate. Non-ionic surfactants are preferred. The most preferred surfactant for including in the emulsion is polysorbate 80 (polyoxyethylene sorbitan monooleate; Tween 80). Mixtures of surfactants can be used e.g. Tween 80/Span 85 mixtures. A combination of a polyoxyethylene sorbitan ester and an octoxynol is also suitable. Another useful combination comprises laureth 9 plus a polyoxyethylene sorbitan ester and/or an octoxynol. 20 Useful amounts of surfactants (% by weight) are: polyoxyethylene sorbitan esters (such as Tween 80) 0.01 to 1%, in particular about 0.1%; octyl- or nonylphenoxy polyoxyethanols (such as Triton X-100, or other detergents in the Triton series) 0.001 to 0.1 %, in particular 0.005 to 0.02%; polyoxyethylene ethers (such as laureth 9) 0.1 to 20 %, e.g. 0.1 to 10 % and in particular 0.1 to 1 % or about 0.5%. Squalene-containing emulsions are preferred, particularly those containing polysorbate 80. 25 Specific oil-in-water emulsion adjuvants useful with the invention include, but are not limited to: e A submicron emulsion of squalene, polysorbate 80, and sorbitan trioleate. The composition of the emulsion by volume can be about 5% squalene, about 0.5% polysorbate 80 and about 0.5% Span 85. In weight terms, these ratios become 4.3% squalene, 0.5% polysorbate 80 and 0.48% Span 85. This adjuvant is known as 'MF59' [69-71], as described in more detail in 30 Chapter 10 of ref. 65 and chapter 12 of ref. 72. The MF59 emulsion advantageously includes citrate ions e.g. 10mM sodium citrate buffer. e A submicron emulsion of squalene, a tocopherol, and polysorbate 80. These emulsions may have from 2 to 10% squalene, from 2 to 10% tocopherol and from 0.3 to 3% polysorbate 80, and the weight ratio of squalene:tocopherol is preferably <1 (e.g. 0.90) as this can provide a 35 more stable emulsion. Squalene and polysorbate 80 may be present at a volume ratio of about 5:2 or at a weight ratio of about 11:5. One such emulsion can be made by dissolving Tween 80 -16in PBS to give a 2% solution, then mixing 90ml of this solution with a mixture of (5g of DL-a-tocopherol and 5ml squalene), then microfluidising the mixture. The resulting emulsion has submicron oil droplets e.g. with an average diameter of between 100 and 250nm, preferably about 180nm. The emulsion may also include a 3-de-O-acylated monophosphoryl 5 lipid A (3d-MPL). Another useful emulsion of this type may comprise, per human dose, 0.5-10 mg squalene, 0.5-11 mg tocopherol, and 0.1-4 mg polysorbate 80 [73]. e An emulsion of squalene, a tocopherol, and a Triton detergent (e.g. Triton X-100). The emulsion may also include a 3d-MPL (see below). The emulsion may contain a phosphate buffer. 10 e An emulsion comprising a polysorbate (e.g. polysorbate 80), a Triton detergent (e.g. Triton X-100) and a tocopherol (e.g. an a-tocopherol succinate). The emulsion may include these three components at a mass ratio of about 75:11:10 (e.g. 750pig/ml polysorbate 80, 110pig/ml Triton X-100 and 100pg/ml a-tocopherol succinate), and these concentrations should include any contribution of these components from antigens. The emulsion may also include squalene. 15 The emulsion may also include a 3d-MPL. The aqueous phase may contain a phosphate buffer. e An emulsion of squalane, polysorbate 80 and poloxamer 401 ("PluronicTM L121"). The emulsion can be formulated in phosphate buffered saline, pH 7.4. This emulsion is a useful delivery vehicle for muramyl dipeptides, and has been used with threonyl-MDP in the "SAF-1" adjuvant [74] (0.05-1% Thr-MDP, 5% squalane, 2.5% Pluronic L121 and 0.2% 20 polysorbate 80). It can also be used without the Thr-MDP, as in the "AF" adjuvant [75] (5% squalane, 1.25% Pluronic L121 and 0.2% polysorbate 80). Microfluidisation is preferred. e An emulsion comprising squalene, an aqueous solvent, a polyoxyethylene alkyl ether hydrophilic nonionic surfactant (e.g. polyoxyethylene (12) cetostearyl ether) and a hydrophobic nonionic surfactant (e.g. a sorbitan ester or mannide ester, such as sorbitan 25 monoleate or 'Span 80'). The emulsion is preferably thermoreversible and/or has at least 90% of the oil droplets (by volume) with a size less than 200 nm [76]. The emulsion may also include one or more of: alditol; a cryoprotective agent (e.g. a sugar, such as dodecylmaltoside and/or sucrose); and/or an alkylpolyglycoside. The emulsion may include a TLR4 agonist [77]. Such emulsions may be lyophilized. 30 e An emulsion of squalene, poloxamer 105 and Abil-Care [78]. The final concentration (weight) of these components in adjuvanted vaccines are 5% squalene, 4% poloxamer 105 (pluronic polyol) and 2% Abil-Care 85 (Bis-PEG/PPG-16/16 PEG/PPG-16/16 dimethicone; caprylic/capric triglyceride). e An emulsion having from 0.5-50% of an oil, 0.1-10% of a phospholipid, and 0.05-5% of a 35 non-ionic surfactant. As described in reference 79, preferred phospholipid components are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, -17phosphatidylglycerol, phosphatidic acid, sphingomyelin and cardiolipin. Submicron droplet sizes are advantageous. e A submicron oil-in-water emulsion of a non-metabolisable oil (such as light mineral oil) and at least one surfactant (such as lecithin, Tween 80 or Span 80). Additives may be included, 5 such as QuilA saponin, cholesterol, a saponin-lipophile conjugate (such as GPI-0100, described in reference 80, produced by addition of aliphatic amine to desacylsaponin via the carboxyl group of glucuronic acid), dimethyidioctadecylammonium bromide and/or N,N dioctadecyl-N,N-bis (2-hydroxyethyl)propanediamine. e An emulsion in which a saponin (e.g. QuilA or QS21) and a sterol (e.g. a cholesterol) are 10 associated as helical micelles [81]. e An emulsion comprising a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol, and a non-ionic hydrophilic surfactant (e.g. an ethoxylated fatty alcohol and/or polyoxyethylene polyoxypropylene block copolymer) [82]. e An emulsion comprising a mineral oil, a non-ionic hydrophilic ethoxylated fatty alcohol, and 15 a non-ionic lipophilic surfactant (e.g. an ethoxylated fatty alcohol and/or polyoxyethylene polyoxypropylene block copolymer) [82]. As mentioned above, oil-in-water emulsions comprising squalene are particularly preferred. In some embodiments, the squalene concentration in a vaccine dose may be in the range of 5-15mg (i.e. a concentration of 10-30mg/ml, assuming a 0.5ml dose volume). It is possible, though, to reduce the 20 concentration of squalene [83,84] e.g. to include <5mg per dose, or even <1.1mg per dose. For example, a human dose may include 9.75mg squalene per dose (as in the FLUADTM product: 9.75mg squalene, 1.175mg polysorbate 80, 1.175mg sorbitan trioleate, in a 0.5ml dose volume), or it may include a fractional amount thereof e.g. 3/4, 2/3, 1/2, 2/5, 1/3, 1/4, 1/5, 1/6, 1/7, 1/8, 1/9, or 1/10. For example, a composition may include 4.875 squalene per dose (and thus 0.588mg each of polysorbate 25 80 and sorbitan trioleate), 3.25mg squalene/dose, 2.438mg/dose, 1.95mg/dose, 0.975mg/dose, etc. Any of these fractional dilutions of the FLUAD

TM

-strength MF59 can be used with the invention, while maintaining a squalene:polysorbate-80:sorbitan-trioleate ratio of 8.3:1:1 (by mass). Further Antigens for use with the invention Compositions and kits of the invention can also comprise one or more further antigens from other 30 pathogens, particularly from bacteria and/or viruses. Preferred one or more further antigens are selected from: e a pneumococcal antigen e a diphtheria toxoid ('D') e a tetanus toxoid ('T') 35 e a pertussis antigen ('P'), which is typically acellular ('aP') e a hepatitis B virus (HBV) surface antigen ('HBsAg') -18e a hepatitis A virus (HAV) antigen e a conjugated Haemophilus influenzae type b capsular saccharide ('Hib') e inactivated poliovirus vaccine (IPV) e a conjugated N.meningitidis serogroup A capsular saccharide ('MenA') 5 e a conjugated N.meningitidis serogroup W135 capsular saccharide ('MenW135') e a conjugated N.meningitidis serogroup Y capsular saccharide ('MenY') One or more further antigen can be used. The following combinations of antigens are particularly preferred for use in compositions and kits of the invention: e MenC-PnC. 10 e D-T-Pa-MenC. e D-T-Pa-Hib-MenC; D-T-Pa-IPV-MenC; D-T-Pa-HBsAg-MenC; D-T-Pa-MenC-PnC. e D-T-Pa-HBsAg-IPV-MenC; D-T-Pa-HBsAg-MenC-PnC. e D-T-Pa-HBsAg-IPV-Hib-MenC; D-T-Pa-HBsAg- Hib-MenC-MenA. e D-T-Pa-HBsAg-IPV-Hib-MenC-MenA; D-T-Pa-HBsAg-IPV-Hib-MenC-PnC. 15 These compositions may consist of the antigens listed, or may further include antigens from additional pathogens. Thus they can be used individually, or as components of further vaccines. Conjugated N. meningitidis saccharides Further antigens can include conjugated meningococcal antigens. Conjugated meningococcal antigens comprise capsular saccharide antigens from Neisseria meningitidis conjugated to carrier 20 proteins. Conjugated monovalent vaccines against serogroup C have been approved for human use, and include MENJUGATETM [85], MENINGITECTM and NEISVAC-CTM. Mixtures of conjugates from serogroups A+C are known [86,87] and mixtures of conjugates from serogroups A+C+W135+Y have been reported [88-91] and were approved in 2005 as the MENACTRATM product. 25 The invention may include saccharide from one or more of serogroups A, C, W135 and/or Y e.g. A, C, W135, Y, A+C, C+W135, C+Y, A+C+W135, A+C+Y, C+W135+Y, A+C+W135+Y. The meningococcal serogroup A capsular saccharide is a homopolymer of (aIl->6)-linked N-acetyl D-mannosamine-1-phosphate, with partial O-acetylation in the C3 and C4 positions. Acetylation at the C-3 position can be 70-95%. Conditions used to purify the saccharide can result in 30 de-O-acetylation (e.g. under basic conditions), but it is preferred to retain OAc at this C-3 position. Thus, preferably at least 50% (e.g. at least 60%, 70%, 80%, 90%, 95% or more) of the mannosamine residues are 0-acetylated at the C-3 position. The meningococcal serogroup C capsular saccharide is an a2--9-linked homopolymer of sialic acid (N-acetylneuraminic acid), typically with O-acetyl (OAc) groups at C-7 or C-8 residues. The 35 compound is represented as: ->9)- Neu p NAc 7/8 OAc-(a2->. Some MenC strains (-12% of invasive isolates) produce a polysaccharide that lacks this OAc group. The presence or absence of -19- OAc groups generates unique epitopes, and the specificity of antibody binding to the saccharide may affect its bactericidal activity against O-acetylated (OAc-) and de-O-acetylated (OAc+) strains [92 94]. Licensed MenC conjugate vaccines include both OAc- (NEISVAC-C T M ) and OAc+

(MENJUGATE

TM & MENINGITECTM) saccharides. Serogroup C saccharides used with the 5 invention may be prepared from either OAc+ or OAc- strains. Preferred strains for production of serogroup C conjugates are OAc+ strains, preferably of serotype 16, preferably of serosubtype P1.7a,1. Thus C:16:P1.7a,1 OAc+ strains are preferred. OAc+ strains in serosubtype P1.1 are also useful, such as the C1I strain. The serogroup W135 saccharide is a polymer of sialic acid-galactose disaccharide units. Like the 10 serogroup C saccharide, it has variable O-acetylation, but at sialic acid 7 and 9 positions [95]. The structure is written as: -4)-D-Neup5Ac(7/9OAc)-a-(2--6)-D-Gal-a-(1 The serogroup Y saccharide is similar to the serogroup W135 saccharide, except that the disaccharide repeating unit includes glucose instead of galactose. Like serogroup W135, it has variable O-acetylation at sialic acid 7 and 9 positions [95]. The serogroup Y structure is written as: 15 ->4)-D-Neup5Ac(7/9OAc)-a-(2--6)-D-Glc-a-(1-* The MENJUGATETM and MENINGITECTM products use a CRM197 carrier protein, and this carrier can also be used according to the invention. The NEISVAC-CTM product uses a tetanus toxoid carrier protein, and this carrier can also be used according to the invention, as can diphtheria toxoid. Another useful carrier protein for the meningococcal conjugates is protein D from Haemophilus 20 influenzae, which is not present in any existing approved conjugate vaccines. The saccharide of further antigens may comprise full-length saccharides as prepared from meningococci, and/or it may comprise fragments of full-length saccharides. The saccharides of further antigens are preferably shorter than the native capsular saccharides seen in bacteria. Thus the saccharides of further antigens are preferably depolymerised, with depolymerisation occurring after 25 saccharide purification but before conjugation. Depolymerisation reduces the chain length of the saccharides. One depolymerisation method involves the use of hydrogen peroxide [88]. Hydrogen peroxide is added to a saccharide (e.g. to give a final H 2 0 2 concentration of 1%), and the mixture is then incubated (e.g. at about 55'C) until a desired chain length reduction has been achieved. Another depolymerisation method involves acid hydrolysis [89]. Other depolymerisation methods are known 30 in the art. The saccharides used to prepare conjugates for use according to the invention may be obtainable by any of these depolymerisation methods. Depolymerisation can be used in order to provide an optimum chain length for immunogenicity and/or to reduce chain length for physical manageability of the saccharides. Preferred saccharides have the following range of average degrees of polymerisation (Dp): A=10-20; C=12-22; W135=15-25; Y=15-25. In terms of molecular weight, 35 rather than Dp, preferred ranges are, for all serogroups: <100kDa; 5kDa-75kDa; 7kDa-5OkDa; 8kDa 35kDa; 12kDa-25kDa; 15kDa-22kDa. -20- Meningococcal conjugates with a saccharide:protein ratio (w/w) of between 1:10 (i.e. excess protein) and 10:1 (i.e. excess saccharide) may be used in further antigens e.g. ratios between 1:5 and 5:1, between 1:2.5 and 2.5:1, or between 1:1.25 and 1.25:1. A ratio of 1:1 can be used. Typically, a composition will include between 1Vg and 20pg (measured as saccharide) per dose of 5 each further antigen serogroup that is present. Meningococcal conjugates may or may not be adsorbed to an aluminium salt adjuvant. Meningococcal conjugates may be lyophilised prior to use according to the invention. If lyophilised, the composition may include a stabiliser such as mannitol. It may also include sodium chloride. Conjugated pneumococcal saccharides 10 Further antigens can include conjugated pneumococcal antigens. Conjugated pneumococcal antigens comprise capsular saccharide antigens from Streptococcus pneumoniae conjugated to carrier proteins [e.g. refs. 96 to 98]. It is preferred to include saccharides from more than one serotype of S.pneumoniae: mixtures of polysaccharides from 23 different serotype are widely used, as are conjugate vaccines with polysaccharides from between 5 and 11 different serotypes [99]. For 15 example, PREVNARTM [100] contains antigens from seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) with each saccharide individually conjugated to CRM197 by reductive amination, with 2Vg of each saccharide per 0.5ml dose (4pg of serotype 6B). Further antigens preferably include saccharide antigens for at least serotypes 6B, 14, 19F and 23F. Further serotypes are preferably selected from: 1, 3, 4, 5, 7F, 9V and 18C. 7-valent (as in 20 PREVNARTM), 9-valent (e.g. the 7 serotypes from PREVNAR, plus 1 & 5), 10-valent (e.g. the 7 serotypes from PREVNAR, plus 1, 5 & 7F) and 11-valent (e.g. the 7 serotypes from PREVNAR, plus 1, 3, 5 & 7F) coverage of pneumococcal serotypes is particularly useful. The saccharide moiety of the conjugate may comprise full-length saccharides as prepared from pneumococci, and/or it may comprise fragments of full-length saccharides. The saccharides used 25 according to the invention are preferably shorter than the native capsular saccharides seen in bacteria, as described above for meningococcal conjugates. Pneumococcal conjugates with a saccharide:protein ratio (w/w) of between 1:10 (i.e. excess protein) and 10:1 (i.e. excess saccharide) may be used e.g. ratios between 1:5 and 5:1, between 1:2.5 and 2.5:1, or between 1:1.25 and 1.25:1. 30 The PREVNARTM product use a CRM197 carrier protein, and this carrier can also be used according to the invention. Alternative carriers for use with pneumococcal saccharides include, but are not limited to, a tetanus toxoid carrier, a diphtheria toxoid carrier, and/or a H.influenzae protein D carrier. The use of multiple carriers for mixed pneumococcal serotypes may be advantageous [101] e.g. to include both a H.influenzae protein D carrier and e.g. a tetanus toxoid carrier and/or a 35 diphtheria toxoid carrier. For example, one or more (preferably all) of serotypes 1, 4, 5, 6B, 7F, 9V, -21- 14 and 23F may be conjugated to a H.influenzae protein D carrier, serotype 18C may be conjugated to a tetanus toxoid, and serotype 19F may be conjugated to a diphtheria toxoid carrier. Typically, a composition will include between 1pg and 20pg (measured as saccharide) per dose of each serotype that is present. 5 Pertussis antigens Further antigens can include pertussis antigens. Bordetella pertussis causes whooping cough. Pertussis antigens in vaccines are either cellular (whole cell, in the form of inactivated B.pertussis cells) or acellular. Preparation of cellular pertussis antigens is well documented [e.g. see chapter 21 of ref. 102] e.g. it may be obtained by heat inactivation of phase I culture of B.pertussis. Preferably, 10 however, the invention uses acellular antigens. Where acellular antigens are used, it is preferred to use one, two or (preferably) three of the following antigens: (1) detoxified pertussis toxin (pertussis toxoid, or 'PT'); (2) filamentous hemagglutinin ('FHA'); (3) pertactin (also known as the '69 kiloDalton outer membrane protein'). These three antigens are preferably prepared by isolation from B.pertussis culture grown in modified 15 Stainer-Scholte liquid medium. PT and FHA can be isolated from the fermentation broth (e.g. by adsorption on hydroxyapatite gel), whereas pertactin can be extracted from the cells by heat treatment and flocculation (e.g. using barium chloride). The antigens can be purified in successive chromatographic and/or precipitation steps. PT and FHA can be purified by, for example, hydrophobic chromatography, affinity chromatography and size exclusion chromatography. Pertactin 20 can be purified by, for example, ion exchange chromatography, hydrophobic chromatography and size exclusion chromatography. FHA and pertactin may be treated with formaldehyde prior to use according to the invention. PT is preferably detoxified by treatment with formaldehyde and/or glutaraldehyde. As an alternative to this chemical detoxification procedure the PT may be a mutant PT in which enzymatic activity has been reduced by mutagenesis [103], but detoxification by 25 chemical treatment is preferred. Acellular pertussis antigens are preferably adsorbed onto one or more aluminium salt adjuvants. As an alternative, they may be added in an unadsorbed state. Where pertactin is added then it is preferably already adsorbed onto an aluminum hydroxide adjuvant. PT and FHA may be adsorbed onto an aluminum hydroxide adjuvant or an aluminum phosphate. Adsorption of all of PT, FHA and 30 pertactin to aluminum hydroxide is most preferred. Compositions will typically include: 1-50 pg/dose PT; 1-50 pg/dose FHA; and 1-50 pg pertactin. Preferred amounts are about 25pg/dose PT, about 25pg/dose FHA and about 8pg/dose pertactin. As well as PT, FHA and pertactin, it is possible to include fimbriae (e.g. agglutinogens 2 and 3) in an acellular pertussis vaccine. -22- Inactivated poliovirus vaccine Further antigens can include inactivated poliovirus antigens. Poliovirus causes poliomyelitis. Rather than use oral poliovirus vaccine, further antigens use IPV, as disclosed in more detail in chapter 24 of reference 102. 5 Polioviruses may be grown in cell culture, and a preferred culture uses a Vero cell line, derived from monkey kidney. Vero cells can conveniently be cultured on microcarriers. After growth, virions may be purified using techniques such as ultrafiltration, diafiltration, and chromatography. Prior to administration to patients, polioviruses must be inactivated, and this can be achieved by treatment with formaldehyde. 10 Poliomyelitis can be caused by one of three types of poliovirus. The three types are similar and cause identical symptoms, but they are antigenically very different and infection by one type does not protect against infection by others. It is therefore preferred to use three poliovirus antigens in the invention: poliovirus Type 1 (e.g. Mahoney strain), poliovirus Type 2 (e.g. MEF-1 strain), and poliovirus Type 3 (e.g. Saukett strain). The viruses are preferably grown, purified and inactivated 15 individually, and are then combined to give a bulk trivalent mixture for use with the invention. Quantities of IPV are typically expressed in the 'DU' unit (the "D-antigen unit" [104]). It is preferred to use between 1-100 DU per viral type per dose e.g. about 80 DU of Type 1 poliovirus, about 16 DU of type 2 poliovirus, and about 64 DU of type 3 poliovirus. Poliovirus antigens are preferably not adsorbed to any aluminium salt adjuvant before being used to 20 make compositions of the invention, but they may become adsorbed onto aluminum adjuvant(s) in the vaccine composition during storage. Diphtheria toxoid Further antigens can include diphtheria toxoid antigens. Corynebacterium diphtheriae causes diphtheria. Diphtheria toxin can be treated (e.g. using formalin or formaldehyde) to remove toxicity 25 while retaining the ability to induce specific anti-toxin antibodies after injection. These diphtheria toxoids are used in diphtheria vaccines, and are disclosed in more detail in chapter 13 of reference102. Preferred diphtheria toxoids are those prepared by formaldehyde treatment. The diphtheria toxoid can be obtained by growing C.diphtheriae in growth medium (e.g. Fenton medium, or Linggoud & Fenton medium), which may be supplemented with bovine extract, followed by 30 formaldehyde treatment, ultrafiltration and precipitation. The toxoided material may then be treated by a process comprising sterile filtration and/or dialysis. Quantities of diphtheria toxoid can be expressed in international units (IU). For example, the NIBSC supplies the 'Diphtheria Toxoid Adsorbed Third International Standard 1999' [105,106], which contains 160 IU per ampoule. As an alternative to the IU system, the 'Lf' unit ("flocculating units" or 35 the "limes flocculating dose") is defined as the amount of toxoid which, when mixed with one International Unit of antitoxin, produces an optimally flocculating mixture [107]. For example, the -23- NIBSC supplies 'Diphtheria Toxoid, Plain' [108], which contains 300 LF per ampoule, and also supplies 'The 1st International Reference Reagent For Diphtheria Toxoid For Flocculation Test' [109] which contains 900 LF per ampoule. Compositions typically include between 20 and 80 Lf of diphtheria toxoid, typically about 50 Lf. 5 By IU measurements, compositions will typically include at least 301U/dose. The diphtheria toxoid is preferably adsorbed onto an aluminium hydroxide adjuvant. Tetanus toxoid Further antigens can include tetanus toxoid antigens. Clostridium tetani causes tetanus. Tetanus toxin can be treated to give a protective toxoid. The toxoids are used in tetanus vaccines, and are disclosed 10 in more detail in chapter 27 of reference 102. Preferred tetanus toxoids are those prepared by formaldehyde treatment. The tetanus toxoid can be obtained by growing C.tetani in growth medium (e.g. a Latham medium derived from bovine casein), followed by formaldehyde treatment, ultrafiltration and precipitation. The material may then be treated by a process comprising sterile filtration and/or dialysis. 15 Quantities of tetanus toxoid can be expressed in international units (IU). For example, the NIBSC supplies the 'Tetanus Toxoid Adsorbed Third International Standard 2000' [110,111], which contains 469 IU per ampoule. As an alternative to the IU system, the 'Lf' unit ("flocculating units" or the "limes flocculating dose") is defined as the amount of toxoid which, when mixed with one International Unit of antitoxin, produces an optimally flocculating mixture [107]. For example, the 20 NIBSC supplies 'The 1st International Reference Reagent for Tetanus Toxoid For Flocculation Test' [112] which contains 1000 LF per ampoule. Compositions will typically include between 5 and 50 Lf of diphtheria toxoid, typically about 20 Lf. By IU measurements, compositions will typically include at least 401U/dose. The tetanus toxoid may be adsorbed onto an aluminium hydroxide adjuvant, but this is not necessary 25 (e.g. adsorption of between 0-10% of the total tetanus toxoid can be used). Hepatitis A virus antigens Further antigens can include hepatitis A virus antigens. Hepatitis A virus (HAV) is one of the known agents which causes viral hepatitis. HAV vaccines are disclosed in chapter 15 of reference 102. A preferred HAV component is based on inactivated virus, and inactivation can be achieved by 30 formalin treatment. Virus can be grown on human embryonic lung diploid fibroblasts, such as MRC-5 cells. A preferred HAV strain is HM175, although CR326F can also be used. The cells can be grown under conditions that permit viral growth. The cells are lysed, and the resulting suspension can be purified by ultrafiltration and gel permeation chromatography. The amount of HAV antigen, measured in EU (Elisa Units), is typically at least about 500EU/ml. -24- Hepatitis B virus surface antigen Further antigens can include hepatitis B virus antigens. Hepatitis B virus (HBV) is one of the known agents which causes viral hepatitis. The HBV virion consists of an inner core surrounded by an outer protein coat or capsid, and the viral core contains the viral DNA genome. The major component of 5 the capsid is a protein known as HBV surface antigen or, more commonly, 'HBsAg', which is typically a 226-amino acid polypeptide with a molecular weight of -24 kDa. All existing hepatitis B vaccines contain HBsAg, and when this antigen is administered to a normal vaccinee it stimulates the production of anti-HBsAg antibodies which protect against HBV infection. For vaccine manufacture, HBsAg has been made in two ways. The first method involves purifying 10 the antigen in particulate form from the plasma of chronic hepatitis B carriers, as large quantities of HBsAg are synthesized in the liver and released into the blood stream during an HBV infection. The second way involves expressing the protein by recombinant DNA methods. HBsAg for use with the method of the invention is preferably recombinantly expressed in yeast cells. Suitable yeasts include, for example, Saccharomyces (such as S.cerevisiae) or Hanensula (such as H.polymorpha) hosts. 15 The HBsAg is preferably non-glycosylated. Unlike native HBsAg (i.e. as in the plasma-purified product), yeast-expressed HBsAg is generally non-glycosylated, and this is the most preferred form of HBsAg for use with the invention, because it is highly immunogenic and can be prepared without the risk of blood product contamination. The HBsAg will generally be in the form of substantially-spherical particles (average diameter of 20 about 20nm), including a lipid matrix comprising phospholipids. Yeast-expressed HBsAg particles may include phosphatidylinositol, which is not found in natural HBV virions. The particles may also include a non-toxic amount of LPS in order to stimulate the immune system [113]. Preferred HbsAg is in the form of particles including a lipid matrix comprising phospholipids, phosphatidylinositol and polysorbate 20. 25 All known HBV subtypes contain the common determinant 'a'. Combined with other determinants and subdeterminants, nine subtypes have been identified: aywl, ayw2, ayw3, ayw4, ayr, adw2, adw4, adrq- and adrq+. Besides these subtypes, other variants have emerged, such as HBV mutants that have been detected in immunised individuals ("escape mutants"). The most preferred HBV subtype for use with the invention is subtype adw2. 30 In addition to the 'S' sequence, a surface antigen may include all or part of a pre-S sequence, such as all or part of a pre-SI and/or pre-S2 sequence. A preferred method for HBsAg purification involves, after cell disruption: ultrafiltration; size exclusion chromatography; anion exchange chromatography; ultracentrifugation; desalting; and sterile filtration. Lysates may be precipitated after cell disruption (e.g. using a polyethylene glycol), 35 leaving HBsAg in solution, ready for ultrafiltration. -25- After purification HBsAg may be subjected to dialysis (e.g. with cysteine), which can be used to remove any mercurial preservatives such as thimerosal that may have been used during HBsAg preparation [114]. Quantities of HBsAg are typically expressed in micrograms, and a typical amount of HBsAg per 5 vaccine dose is between 5 and 5 Vg e.g. 10pg/dose. Although HBsAg may be adsorbed to an aluminium hydroxide adjuvant in the final vaccine (as in the well-known ENGERIX-BM product), or may remain unadsorbed, it will generally be adsorbed to an aluminium phosphate adjuvant [115]. Con jugated Haemophilus influenzae type b antigens 10 Further antigens can include conjugated Haemophilus influenzae type b ('Hib') antigens. Hib causes bacterial meningitis. Hib vaccines are typically based on the capsular saccharide antigen [e.g. chapter 14 of ref. 102], the preparation of which is well documented [e.g. references 116 to 125]. The Hib saccharide can be conjugated to a carrier protein in order to enhance its immunogenicity, especially in children. Typical carrier proteins are tetanus toxoid, diphtheria toxoid, the CRM197 15 derivative of diphtheria toxoid, H.influenzae protein D, and an outer membrane protein complex from serogroup B meningococcus. The carrier protein in the Hib conjugate is preferably different from the carrier protein(s) in the meningococcal conjugate(s), but the same carrier can be used in some embodiments. Tetanus toxoid is the preferred carrier, as used in the product commonly referred to as 'PRP-T'. 20 PRP-T can be made by activating a Hib capsular polysaccharide using cyanogen bromide, coupling the activated saccharide to an adipic acid linker (such as (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide), typically the hydrochloride salt), and then reacting the linker-saccharide entity with a tetanus toxoid carrier protein. The saccharide moiety of the conjugate may comprise full-length polyribosylribitol phosphate (PRP) 25 as prepared from Hib bacteria, and/or fragments of full-length PRP. Hib conjugates with a saccharide:protein ratio (w/w) of between 1:5 (i.e. excess protein) and 5:1 (i.e. excess saccharide) may be used e.g. ratios between 1:2 and 5:1 and ratios between 1:1.25 and 1:2.5. In preferred vaccines, however, the weight ratio of saccharide to carrier protein is between 1:2 and 1:4, preferably between 1:2.5 and 1:3.5. In vaccines where tetanus toxoid is present both as an 30 antigen and as a carrier protein then the weight ratio of saccharide to carrier protein in the conjugate may be between 1:0.3 and 1:2 [126]. Amounts of Hib conjugates are generally given in terms of mass of saccharide (i.e. the dose of the conjugate (carrier + saccharide) as a whole is higher than the stated dose) in order to avoid variation due to choice of carrier. A typical amount of Hib saccharide per dose is between 1-30pg, preferably 35 about 10pg. -26- Administration of the Hib conjugate preferably results in an anti-PRP antibody concentration of >0.15pg/ml, and more preferably >1 g/ml, and these are the standard response thresholds. Hib conjugates may be lyophilised prior to their use according to the invention. Further components may also be added prior to freeze-drying e.g. as stabilizers. Preferred stabilizers for inclusion are 5 lactose, sucrose and mannitol, as well as mixtures thereof e.g. lactose/sucrose mixtures, sucrose/mannitol mixtures, etc. The final vaccine may thus contain lactose and/or sucrose. Using a sucrose/mannitol mixture can speed up the drying process. Hib conjugates may or may not be adsorbed to an aluminium salt adjuvant. It is preferred not to adsorb them to an aluminium hydroxide adjuvant. 10 Mixing of oligonucleotide and polymer with MenB antigen Immunogenic compositions of the invention can conveniently be prepared by mixing an aqueous suspension of the oligonucleotide/polymer complex with an antigen. The complex is typically maintained in liquid form, hence providing an easy way of co-formulating them. In some embodiments one or both of the suspensions includes an immunogen so that the mixing 15 provides an immunogenic composition of the invention. Where two liquids are mixed the volume ratio for mixing can vary (e.g. between 20:1 and 1:20, between 10:1 and 1:10, between 5:1 and 1:5, between 2:1 and 1:2, etc.) but is ideally about 1:1. The concentration of components in the two suspensions can be selected so that a desired final concentration is achieved after mixing e.g. both may be prepared at 2x strength such that 1:1 mixing 20 provides the final desired concentrations. Various concentrations of oligonucleotide and polycationic polymer can be used e.g. any of the concentrations used in references 58, 61, 62 or 127. For example, a polycationic oligopeptide can be present at 1100 VM, 1000 VM, 350 VM, 220VM, 200 VM, 110 VM, 100 VM, 11 VM, 10 1 aM, l 1 aM, 500nM, 50nM, etc. An oligonucleotide can be present at 44 nM, 40 nM, 20nM, 14 nM, 4.4 nM, 25 4 nM, 2 nM, etc. A polycationic oligopeptide concentration of less than 2000 nM is typical. For SEQ ID NOs: 1 & 2, mixed at a molar ratio of 1:25, the concentrations in mg/mL in three embodiments of the invention may thus be 0.3 11 & 1.322, or 0.109 & 0.463, or 0.031 and 0.132. Some immunogenic compositions of the invention comprise an aluminium salt and a complex of the immunostimulatory oligonucleotide and polycationic polymer. In such compositions, an aluminium 30 salt and a complex of the immunostimulatory oligonucleotide and polycationic polymer are typically both particulate. The mean particle diameter of aluminium salt adjuvants is typically in the order of 1-20pm [66,128]. This is also the size range for complexes seen in IC31TM. When such particles are combined, the average diameter of the salt particles may be substantially the same as the average diameter of the complexes. In other embodiments, however, the average diameter of the salt particles 35 may be smaller than the average size of the complexes. In other embodiments, the average diameter of the salt particles may be larger than the average size of the complexes. Where the average -27diameters differ, the larger diameter may be greater by a factor of at least 1.05x e.g. 1.lx, 1.2x, 1.3x, 1.4x, 1.5x, 2x, 2.5x, 3x or more. If either the salt or the complex has particles with a range of diameters, but the average diameters differ, the ranges may or may not overlap. Thus the largest salt particle may be smaller than the smallest complex particles, or the largest complex particles may be 5 smaller than the smallest salt particles. Because the particles are generally too large to be filter sterilised, sterility of an immunogenic composition of the invention will typically be achieved by preparing the complex, and where appropriate, the aluminium salt, under sterile conditions, and then mixing them under sterile conditions. For instance, the components of the complex could be filter sterilised. In some 10 embodiments, these sterile complexes could then be mixed with an autoclaved (sterile) aluminium salt adjuvant to provide a sterile adjuvant composition. This sterile adjuvant can then be mixed with a sterile immunogen to give an immunogenic composition suitable for patient administration. The density of aluminium salt particles is typically different from the density of a complex of immunostimulatory oligonucleotide and polycationic polymer, which means that the two particles 15 might be separated based on density e.g. by sucrose gradient. Pharmaceutical compositions Immunogenic compositions of the invention usually include components in addition to the MenB antigen and the oligonucleotide and polymer e.g. they typically include one or more pharmaceutically acceptable component. Such components may also be present in immunogenic 20 compositions of the invention, originating either in the adjuvant composition or in another composition. A thorough discussion of such components is available in reference 129. A composition may include a preservative such as thiomersal or 2-phenoxyethanol. It is preferred that the vaccine should be substantially free from (e.g. <10pg/ml) mercurial material e.g. thiomersal free. Vaccines containing no mercury are more preferred. Preservative-free vaccines are particularly 25 preferred. a-tocopherol succinate can be included as an alternative to mercurial compounds in influenza vaccines. To control tonicity, a composition may include a physiological salt, such as a sodium salt. Sodium chloride (NaCl) is preferred, which may be present at between 1 and 20 mg/ml. Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate, and/or 30 magnesium chloride, etc. Compositions may have an osmolality of between 200 mOsm/kg and 400 mOsm/kg, e.g. between 240-360 mOsm/kg, maybe within the range of 280-330 mOsm/mg or 290-310 mOsm/kg. The pH of a composition will generally be between 5.0 and 8.1, and more typically between 6.0 and 8.0 e.g. 6.5 and 7.5, or between 7.0 and 7.8. -28- A composition is preferably sterile. A composition is preferably non-pyrogenic e.g. containing <1 EU (endotoxin unit, a standard measure) per dose, and preferably <0.1 EU per dose. A composition is preferably gluten free. An immunogenic composition may include material for a single immunisation, or may include 5 material for multiple immunisations (i.e. a 'multidose' kit). The inclusion of a preservative is useful in multidose arrangements. As an alternative (or in addition) to including a preservative in multidose compositions, the compositions may be contained in a container having an aseptic adaptor for removal of material. Compositions will generally be in aqueous form at the point of administration. Vaccines are typically 10 administered in a dosage volume of about 0.5ml, although a half dose (i.e. about 0.25ml) may sometimes be administered e.g. to children. In some embodiments of the invention a composition may be administered in a higher dose e.g. about 1ml e.g. after mixing two 0.5ml volumes. Packaging of compositions or kit components Suitable containers for immunogenic compositions and kit components of the invention include vials, 15 syringes (e.g. disposable syringes), etc. These containers should be sterile. The containers can be packaged together to form a kit e.g. in the same box. Where a component is located in a vial, the vial can be made of a glass or plastic material. The vial is preferably sterilized before the composition is added to it. To avoid problems with latex-sensitive subjects, vials are preferably sealed with a latex-free stopper, and the absence of latex in all 20 packaging material is preferred. The vial may include a single dose of vaccine, or it may include more than one dose (a 'multidose' vial) e.g. 10 doses. Useful vials are made of colorless glass. Borosilicate glasses are preferred to soda lime glasses. Vials may have stoppers made of butyl rubber. A vial can have a cap (e.g. a Luer lock) adapted such that a syringe can be inserted into the cap. A vial cap may be located inside a seal or cover, such that the seal or cover has to be removed before 25 the cap can be accessed. A vial may have a cap that permits aseptic removal of its contents, particularly for multidose vials. Where a component is packaged into a syringe, the syringe may have a needle attached to it. If a needle is not attached, a separate needle may be supplied with the syringe for assembly and use. Such a needle may be sheathed. The plunger in a syringe may have a stopper to prevent the plunger from 30 being accidentally removed during aspiration. The syringe may have a latex rubber cap and/or plunger. Disposable syringes contain a single dose of vaccine. The syringe will generally have a tip cap to seal the tip prior to attachment of a needle, and the tip cap may be made of a butyl rubber. If the syringe and needle are packaged separately then the needle is preferably fitted with a butyl rubber shield. Useful syringes are those marketed under the trade name "Tip-Lok"TM. 35 Containers may be marked to show a half-dose volume e.g. to facilitate delivery to children. For instance, a syringe containing a 0.5ml dose may have a mark showing a 0.25ml volume. -29- It is usual in multi-component products to include more material than is needed for subject administration, so that a full final dose volume is obtained despite any inefficiency in material transfer. Thus an individual container may include overfill e.g. of 5-20% by volume. Methods of treatment, and administration of immunogenic compositions 5 Compositions of the invention are suitable for administration to human subjects, and the invention provides a method of raising an immune response in a subject, comprising the step of administering an immunogenic composition of the invention to the subject. The invention also provides a method of raising an immune response in a subject, comprising the step of mixing the contents of the containers of a kit of the invention and administering the mixed 10 contents to the subject. The invention also provides composition or kit of the invention for use as a medicament e.g. for use in raising an immune response in a subject. The invention also provides the use of a MenB antigen (as defined above), an immunostimulatory oligonucleotide and a polycationic polymer, in the manufacture of a medicament for raising an 15 immune response in a subject. These methods and uses will generally be used to generate an antibody response, preferably a protective antibody response. Immunogenic compositions of the invention can be administered in various ways. The usual immunisation route is by intramuscular injection (e.g. into the arm or leg), but other available routes 20 include subcutaneous injection, intranasal, oral, buccal, sublingual, intradermal, transcutaneous, transdermal, etc. Immunogenic compositions prepared according to the invention may be used as vaccines to treat both children and adults. A subject may be less than 1 year old, 1-5 years old, 5-15 years old, 15-55 years old, or at least 55 years old. Subjects for receiving the vaccines may be elderly (e.g. >50 years 25 old, >60 years old, and preferably >65 years), the young (e.g. <;5 years old), hospitalised subjects, healthcare workers, armed service and military personnel, pregnant women, the chronically ill, immunodeficient subjects, people travelling abroad, etc. Aluminium salt adjuvants are routinely used in infant populations, and IC31TM has also been effective in this age group [127,130]. The vaccines are not suitable solely for these groups, however, and may be used more generally in a population. 30 Treatment can be by a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunisation schedule and/or in a booster immunisation schedule. In a multiple dose schedule the various doses may be given by the same or different routes e.g. a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, etc. Administration of more than one dose (typically two doses) is particularly useful in immunologically naive subjects. Multiple doses will 35 typically be administered at least 1 week apart (e.g. about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 12 weeks, about 16 weeks, etc.). -30- General The term "comprising" encompasses "including" as well as "consisting" e.g. a composition "comprising" X may consist exclusively of X or may include something additional e.g. X + Y. The word "substantially" does not exclude "completely" e.g. a composition which is "substantially 5 free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention. The term "about" in relation to a numerical value x is optional and means, for example, x+10%. Unless specifically stated, a process comprising a step of mixing two or more components does not require any specific order of mixing. Thus components can be mixed in any order. Where there are 10 three components then two components can be combined with each other, and then the combination may be combined with the third component, etc. Where animal (and particularly bovine) materials are used in the culture of cells, they should be obtained from sources that are free from transmissible spongiform encaphalopathies (TSEs), and in particular free from bovine spongiform encephalopathy (BSE). Overall, it is preferred to culture cells 15 in the total absence of animal-derived materials. Where a compound is administered to the body as part of a composition then that compound may alternatively be replaced by a suitable prodrug. Where a cell substrate is used for reassortment or reverse genetics procedures, or for viral growth, it is preferably one that has been approved for use in human vaccine production e.g. as in Ph Eur 20 general chapter 5.2.3. MODES FOR CARRYING OUT THE INVENTION Adjuvants IC31 complexes were prepared as disclosed in reference 62. An aluminium hydroxide adjuvant suspension is prepared by standard methods. Where compositions comprise an aluminium hydroxide 25 adjuvant and IC31, adjuvant combinations were made by mixing the aluminium hydroxide adjuvant with IC31 complexes. For Meningococcus (iii) and (iv) below, IC31 was prepared in high and low concentrations (10-fold difference) as disclosed in reference 62 and a squalene-in-water emulsion. For Meningococcus (iv), MF59, was prepared as disclosed in Chapter 10 of reference 65. Adjuvant combinations were made 30 by mixing MF59 with IC 31 high or IC31 " at either a 1:1 volume ratio or a 5:1 volume ratio. Meningococcus (i) The three polypeptides which make up the '5CVMB' vaccine disclosed in reference 1 were adjuvanted with aluminium hydroxide and/or IC31. The polypeptides have amino acid sequences SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15 (see refs. 1 and 131) -31- In a first set of experiments, nine groups of mice received 10pg of antigens, 3mg/mi of aluminium hydroxide and varying doses of IC31. Groups received the following nine compositions, with groups 7-9 receiving the same antigens as 1-6 but differently formulated: Antigen dose (pg) IC31 volume* (pl) Al-H (mg/ml) 1 10 100 3 2 10 50 3 3 10 25 3 4 10 10 3 5 10 0 3 6** 10 100 0 7 10 0 3 8 10 100 3 9** 10 100 0 A standard IC31 suspension was used. 100pl of this suspension gave full-strength. Lower volumes gave lower 5 strengths. To preserve the volume for the lower-strength compositions, buffer was added up to 100pl. ** Embodiments of the invention. Sera from the mice were tested against a panel of meningococcal strains for bactericidal activity. Bactericidal titers from experiment MP03 were as follows against six different strains, A to F: A B C D E F 1 >65536 4096 8192 4096 256 32768 2 >65536 8192 8192 8192 512 >65536 3 >65536 4096 4096 8192 512 32768 4 >65536 2048 4096 4096 512 8192 5 >65536 2048 4096 8192 256 32768 6 >65536 4096 >8192 8192 1024 >65536 7 >65536 2048 4096 4096 256 4096 8 >65536 >8192 >8192 >8192 512 >65536 9 32768 8192 >8192 >8192 4096 >65536 10 Thus the titers obtained with Al-H as the only adjuvant (group 5) were generally improved across the panel by the addition of IC31 at various ratios (groups 1 to 4). The same effect was seen with the different antigen formulation (compare groups 7 and 8). Moreover, when IC31 was used as the only adjuvant, (groups 6 and 9), bactericidal titers were found to be as high, or higher, than Al-H and IC3 1+Al-H, in all six strains. 15 The nine compositions were tested for pH and osmolality. For compositions 1-5, 7 and 8 the pH was in the range of 6.2 to 6.6; compositions 6 and 9 had a slightly higher pH, in the range 6.9 to 7.3. Osmolality of all compositions was in the range of 280-330 mOsm/kg. -32- Meningococcus (ii) A triple-fusion polypeptide containing three variants of fHBP, in the order II-III-I (as disclosed in reference 60; SEQ ID NO: 17 herein), was adjuvanted with aluminium hydroxide and/or IC31. In a first set of experiments, six groups of mice received 20pg of antigen (with or without a 5 purification tag), 3mg/ml of aluminium hydroxide and 100V of IC31. Groups received the following: Antigen dose (pg) Antigen tag IC31 volume (pl) Al-H (mg/ml) 1** 20 No 100 0 2** 20 Yes 100 0 3 20 No 100 3 4 20 Yes 100 3 5 20 No 0 3 6 20 Yes 0 3 ** Embodiments of the invention. Sera from the mice were tested against a panel of meningococcal strains for bactericidal activity. Sera from experiment MP05 were again tested against a panel of strains (25 in total). 56% of strains in group 1 (IC31, no tag) and group 3 (IC31+Al-H, no tag) had a titer >1:1024, while only 36% of 10 strains in group 5 (Al-OH, no tag) had a titer >1:1024. Similarly, 76% of strains in groups 1 and 3 had a titer >1:128 while this titer was only observed in 64% of strains in group 5. Thus, in the absence of a purification tag, the highest bactericidal titers were achieved using IC3 1. Bactericidal titer comparisons of purification-tagged antigens revealed that 84% of strains in group 2 (IC31, tag) had a titer of >1:128. By contrast, 80% of strains in group 4 (IC31+Al-H) and only and 15 76% of strains in group 6 (Al-OH) had a titer of >1:128. Thus, in the presence of a purification tag, highest bacterial titers were achieved with IC31 alone. The tag-free compositions (1, 3 and 5) were tested for pH and osmolality. The pH was in the range of 6.87 to 7.00. Osmolality was in the range of 302-308 mOsm/kg. Further immunogenicity experiments used the fHBPr- 11 antigen in combination with the NadA and 20 287-953 antigens (SEQ ID NOs: 13 and 15) in experiment MPO4, with the same groupings and strain panel. Groups 1 and 3 had a bactericidal titer of >1:128 in 100% of strains tested, compared to only 84% in group 5. With a more stringent threshold of >1:1024, sera from groups 1 and 3 were bactericidal against 88% of strains, compared to only 56% in group 5. Similar results were observed with purification-tagged antigens, where 88% of groups 2 and 4 had a 25 bactericidal titer of >1:128 compared to only 80% of group 6. Thus, the highest anti-meningococcus immune responses were obtained with IC31 alone, which was at least as good as IC31+Al-H and better than Al-H alone. -33- Meningococcus (iii) The three polypeptides which make up the '5CVMB' vaccine disclosed in reference 1 were combined with a tetravalent mixture of meningococcal conjugates against serogroups A, C, W135 and Y. The mixture was adjuvanted with Al-H and/or IC31 (at high or low concentration). 5 Bactericidal titers were as follows against a panel with one strain from each of serogroups A, C, W135 and Y: A C W135 Y Un-immunised <16 <16 <16 <16 No adjuvant 1024 256 128 512 IC3high32768 16384 4096 4096 IC31'"w** 16384 8192 1024 2048 Al-hydroxide 16384 8192 1024 4096 Al-H+IC31high16384 32768 4096 8192 Al-H+IC31'Ow 8192 65536 2048 8192 ** Embodiments of the invention. Thus the best titers against serogroup A were seen when using IC31 alone, and titers against serogroups C, W135 and Y were higher than when using Al-H alone. 10 Meningococcus (iv) The antigens from the meningococcus serogroup B vaccine of reference 1 were adjuvanted with MF59, IC3 h igh, 1C3 1 low or combinations thereof. Sera from immunised mice were tested for their bactericidal activity against various meningococcal strains. Representative results include: Strain-- A B C D E F G H IC31'"w** 1024 256 4096 2048 256 64 512 <16 MF59 + IC31'"w 4096 1024 4096 2048 1024 128 4096 <16 MF59 32768 1024 32768 4096 2048 128 4096 <16 MF59 8192 2048 8192 32768 2048 128 8192 <16 IC31high** 16384 2048 16384 32768 2048 512 4096 <16 ** Embodiments of the invention. 15 Use of IC31 alone elicited the highest bactericidal titers in strains B, D, E, and F, and the second highest titers in strains A, C, and G. These meningococcal B protein antigens were also combined with conjugated saccharide antigens from serogroups A, C, W135 and Y antigens and were tested with the same adjuvant mixtures. Bactericidal titers against a test strain from each serogroup were as follows: Antigen-- A C W135 Y IC31'"w** 16384 8192 1024 2048 -34- MF59 + 1C31'"w 4096 8192 4096 8192 MF59 16384 8192 2048 4096 MF59 8192 16384 4096 4096 IC31high** 32768 16384 4096 4096 ** Embodiments of the invention. Therefore, the highest bactericidal titers were seen when using IC31 for serogroup A, C and W135. Meningococcus (v) A composition containing the three variants of fHBP, in the order II-III-I, + 961 + 287-953 (denoted 5 rMenB1) was adjuvanted with Al-H, IC31, or IC31+Al-H. These compositions were compared with a composition comprising 936-741 + 961 + 287-953 + OMV, which was adjuvanted with Al-H (rMenB2). Sera from immunised mice were tested for their bactericidal activity against 12 meningococcal strains. rMenB1 adjuvanted with IC31 alone was found to elicit a higher % coverage across the 12 strains tested than any other composition (e.g. with >90% coverage, compared to 50% coverage for 10 rMenB2). It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention. REFERENCES [1] Giuliani et al. (2006) Proc Natl Acad Sci U S A 103(29):10834-9. [2] Tettelin et al. (2000) Science 287:1809-1815. [3] WOOO/66741. [4] W099/57280 [5] Martin et al. (1997) J Exp Med 185(7):1173-83. [6] W096/29412. [7] Perkins-Balding et al. (2003) Microbiology 149:3423-35. [8] W001/55182. [9] WO01/38350. [10] WOOO/23595. [11] Madico et al. (2006) J. Immunol. 177:501-10. [12] Schneider et al. (2006) J. Immunol. 176:7566-75. [13] Ram et al. (2003) J Biol Chem 278:50853-62. [14] W098/53851 [15] US-6531131 [16] WOOO/26384. [17] US-6645503 [18] W003/070282. [19] W094/08021 [20] W02004/015099. [21] W02007/144316. -35- [22] W02007/144317. [23] WO02/09643. [24] Katial et al. (2002) Infect. Immun. 70:702-707. [25] US 6,180,111. [26] WO01/34642. [27] W02004/019977. [28] EP-0011243. [29] Fredriksen et al. (1991) NIPH Ann. 14(2):67-80. [30] WO01/91788. [31] W02005/004908. [32] Maiden et al. (1998) PNAS USA 95:3140-3145. [33] W098/56901. [34] W02006/081259. [35] Claassen et al. (1996) 14(10):1001-8. [36] W099/10497. [37] Steeghs et al. (2001) The EMBO Journal 20:6937-6945. [38] WO01/52885. [39] WOOO/25811. [40] WO01/09350. [41] WO02/09746. [42] WO02/062378. [43] W02004/014417. [44] WO03/105890. [45] W02006/024946 [46] Krieg (2003) Nature Medicine 9:831-835. [47] McCluskie et al. (2002) FEMS Immunology and Medical Microbiology 32:179-185. [48] W098/40100. [49] US 6,207,646. [50] US 6,239,116. [51] US 6,429,199. [52] WO01/93905. [53] WO02/32451. [54] Aichinger et al. (2008) Cell Biology International 32:1449-58. [55] Alvarez-Bravo et al. (1994) Biochem J 302:535-8. [56] Nakajima et al. (1997) FEBS Letts 415:64-66. [57] Fritz et al. (2004) Vaccine 22:3274-84. [58] Schellack et al. (2006) Vaccine 24:5461-72. [59] Lingnau et al. (2007) Expert Rev Vaccines 6:741-6. [60] W02004/084938. [61] Kamath et al. (2008) Eur JImmunol 38:1247-56. [62] Riedl et al. (2008) Vaccine 26:3461-8. [63] Kritsch et al. (2005) J Chromatography B 822:263-70. [64] Lingnau et al. (2003) Vaccine 20:3498-508. [65] Vaccine Design: The Subunit and Adjuvant Approach (Powell & Newman) 1995 (ISBN 0-306-44867-X). [66] Clausi et al. (2008) JPharm Sci DOI 10.1002/jps.21390 [67] W02009/081172. [68] Seeber et al. (1991) JParenteral Sci Technol 45:156-9. [69] W090/14837. -36- [70] Podda & Del Giudice (2003) Expert Rev Vaccines 2:197-203. [71] Podda (2001) Vaccine 19: 2673-2680. [72] Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series). ISBN: 1-59259-083-7. Ed. O'Hagan. [73] W02008/043774. [74] Allison & Byars (1992) Res Immunol 143:519-25. [75] Hariharan et al. (1995) Cancer Res 55:3486-9. [76] US-2007/0014805. [77] US-2007/0191314. [78] Suli et al. (2004) Vaccine 22(25-26):3464-9. [79] W095/11700. [80] US patent 6,080,725. [81] W02005/097181. [82] W02006/113373. [83] W02007/052155. [84] W02008/128939. [85] Jones (2001) Curr Opin Investig Drugs 2:47-49. [86] Costantino et al. (1992) Vaccine 10:691-8. [87] Lieberman et al. (1996) JAMA 275:1499-503. [88] WO02/058737. [89] WO03/007985. [90] Rennels et al. (2002) Pediatr Infect Dis J 21:978-979. [91] Campbell et al. (2002) JInfect Dis 186:1848-1851. [92] Arakere & Frasch (1991) Infect. Immun. 59:4349-4356. [93] Michon et al. (2000) Dev. Biol. 103:151-160. [94] Rubinstein & Stein (1998) J. Immunol. 141:4357-4362. [95] W02005/033148. [96] Watson (2000) Pediatr Infect Dis J 19:331-332. [97] Rubin (2000) Pediatr Clin North Am 47:269-285, v. [98] Jedrzejas (2001) Microbiol Mol Biol Rev 65:187-207. [99] Zielen et al. (2000) Infect. Immun. 68:1435-1440. [100] Darkes & Plosker (2002) Paediatr Drugs 4:609-630. [101] W098/51339. [102] Vaccines. (eds. Plotkin & Orenstein). 4th edition, 2004, ISBN: 0-7216-9688-0. [103] Rappuoli et al. (1991) TIBTECH 9:232-238. [104] Module 6 of WHO's The immunological basisfor immunization series (Robertson) [105] Sesardic et al. (2001) Biologicals 29:107-22. [106] NIBSC code: 98/560. [107] Module 1 of WHO's The immunological basisfor immunization series (Galazka). [108] NIBSC code: 69/017. [109] NIBSC code: DIFT. [110] Sesardic et al. (2002) Biologicals 30:49-68. [111] NIBSC code: 98/552. [112] NIBSC code: TEFT. [113] Vanlandschoot et al. (2005) J Gen Virol 86:323-3 1. [114] WO03/066094. [115] W093/24148. [116] Ramsay et al. (2001) Lancet 357(9251):195-196. -37- [117] Lindberg (1999) Vaccine 17 Suppl 2:S28-36. [118] Buttery & Moxon (2000) JR Coll Physicians Lond 34:163-168. [119] Ahmad & Chapnick (1999) Infect Dis Clin North Am 13:113-133, vii. [120] Goldblatt (1998) J. Med. Microbiol. 47:563-567. [121] European patent 0477508. [122] US patent 5,306,492. [123] W098/42721. [124] Conjugate Vaccines (eds. Cruse et al.) ISBN 3805549326, particularly vol. 10:48-114. [125] Hermanson (1996) Bioconjugate Techniques ISBN: 0123423368 or 012342335X. [126] W096/40242. [127] Olafsdottir et al. (2009) Scand J Immunol 69:194-202. [128] Hem & HogenEsch (2007) Expert Rev Vaccines 6:685-98. [129] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472. [130] Kamath et al. (2008) PLoS ONE 3(11):e3683. [131] W02004/032958. -38-

Claims (26)

1. An immunogenic composition comprising (i) a meningococcal serogroup B antigen and (ii) an adjuvant comprising an immunostimulatory oligonucleotide and a polycationic polymer; wherein (i) the immunogenic composition does not include an aluminium salt; (ii) the immunogenic 5 composition does not include an oil-in-water emulsion; (iii) the meningococcal serogroup B antigen does not include a polypeptide comprising an amino acid sequence selected from SEQ ID NOs 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and (iv) the immunogenic composition does not include a fHBP antigen.

2. An immunogenic composition comprising (i) a meningococcal serogroup B antigen; (ii) an 10 adjuvant comprising an immunostimulatory oligonucleotide and a polycationic polymer and; (iii) one or more further antigens selected from a pneumococcal antigen, a diphtheria toxoid, tetanus toxoid, a pertussis antigen, HBsAg, a HAV antigen, a Hib antigen, and/or IPV.

3. An immunogenic composition comprising (i) a purified meningococcal lipooligosaccharide; and (ii) an adjuvant comprising an immunostimulatory oligonucleotide and a polycationic polymer. 15

4. The immunogenic composition of claim 2 or claim 3, wherein said immunogenic composition further comprises one or more of (i) an aluminium salt; and (ii) an oil-in-water emulsion.

5. The immunogenic composition of any preceding claim wherein the oligonucleotide and the polymer are associated with each other to form a complex.

6. The immunogenic composition of any preceding claim, wherein the immunostimulatory 20 oligonucleotide is single-stranded and has between 10 and 100 nucleotides.

7. The immunogenic composition of claim 6, wherein the oligonucleotide is 5'-(IC) 1 3 -3'.

8. The immunogenic composition of any preceding claim, wherein the polycationic polymer is a peptide.

9. The immunogenic composition of claim 8, wherein the peptide includes one or more Leu-Leu 25 dipeptide sequence(s), one or more Lys-Lys dipeptide sequence(s), and/or one or more Arg-Arg dipeptide sequence(s).

10. The immunogenic composition of claim 8 or claim 9, wherein the peptide includes one or more Lys-Leu dipeptide sequence(s) and/or one or more Lys-Leu-Lys tripeptide sequence(s).

11. The immunogenic composition of any of claims 8-10, wherein the peptide has between 5 and 50 30 amino acids.

12. The immunogenic composition of claim 11, wherein the peptide has amino acid sequence KLKLLLLLKLK.

13. The immunogenic composition of any preceding claim, wherein the oligonucleotide and polymer are present at a molar ratio 1:25. -39-

14. A process for preparing the immunogenic composition of any preceding claim, comprising a step of mixing (i) an immunostimulatory oligonucleotide and a polycationic polymer and (ii) a meningococcal serogroup B antigen.

15. A kit comprising: (i) a first container that contains an immunostimulatory oligonucleotide and a 5 polycationic polymer and (ii) a second container that contains a meningococcal serogroup B antigen; wherein the immunogenic composition does not include an aluminium salt; (ii) the immunogenic composition does not include an oil-in-water emulsion; (iii) the meningococcal serogroup B antigen does not include peptide with SEQ IDs 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22; and (iv) the immunogenic composition does not include a fHBP antigen. 10

16. A kit comprising (i) a first container that contains an immunostimulatory oligonucleotide and a polycationic polymer and (ii) a second container that contains a meningococcal serogroup B antigen wherein said meningococcal serogroup B antigen is a purified meningococcal lipooligosaccharide.

17. A kit comprising which comprises (i) a container that contains an immunostimulatory 15 oligonucleotide and a polycationic polymer and (ii) a container that contains a meningococcal serogroup B antigen and (iii) a container that contains one or more further antigens selected from pneumococcal saccharide antigen, diphtheria toxoid, tetanus toxoid, pertussis antigen, HBsAg, HAV antigen, Hib antigen, and/or IPV.

18. An immunogenic composition comprising (i) a 5-valent antigen component consisting of a MenB 20 antigen, a conjugated capsular saccharide from serogroup A N.meningitidis, a conjugated capsular saccharide from serogroup C N.meningitidis, a conjugated capsular saccharide from serogroup W135 N.meningitidis, a conjugated capsular saccharide from serogroup Y N.meningitidis; and (ii) an adjuvant comprising an immunostimulatory oligonucleotide and a polycationic polymer, provided that the immunogenic composition does not include an 25 aluminium salt and does not include an oil-in-water emulsion. Dated this FIFTH day of APRIL 2013 Novartis AG By FB Rice Patent attorney for the applicant -40- SEQUENCE LISTING <110> NOVARTIS AG <120> ADJUVANTED VACCINES FOR SEROGROUP B MENINGOCOCCUS <130> 159359 <140> AU 2011288203 <141> 2011-03-18 <150> PCT/IB2011/051148 <151> 2011-03-18 <150> US 61/315336 <151> 2010-03-18 <150> US 61/317572 <151> 2010-03-25 <160> 28 <170> SeqWin2010, version 1.0 <210> 1 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Immunostimulatory oligonucleotide <220> <221> misc_feature <222> 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 <223> N is INOSINE <400> 1 ncncncncncncncncncncncncnc 26 <210> 2 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Polycationic peptide <400> 2 Lys Leu Lys Leu Leu Leu Leu Leu Lys Leu Lys 1 5 10 <210> 3 <211> 488 <212> PRT <213> Neisseria meningitidis <400> 3 Met Phe Lys Arg Ser Val Ile Ala Met Ala Cys Ile Phe Ala Leu Ser 1 5 10 15 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Ala Cys Gly Gly Gly Gly Gly Gly Ser Pro Asp Val Lys Ser Ala Asp 20 25 30 Thr Leu Ser Lys Pro Ala Ala Pro Val Val Ser Glu Lys Glu Thr Glu 35 40 45 Ala Lys Glu Asp Ala Pro Gln Ala Gly Ser Gln Gly Gln Gly Ala Pro 50 55 60 Ser Ala Gln Gly Ser Gln Asp Met Ala Ala Val Ser Glu Glu Asn Thr 65 70 75 80 Gly Asn Gly Gly Ala Val Thr Ala Asp Asn Pro Lys Asn Glu Asp Glu 85 90 95 Val Ala Gln Asn Asp Met Pro Gln Asn Ala Ala Gly Thr Asp Ser Ser 100 105 110 Thr Pro Asn His Thr Pro Asp Pro Asn Met Leu Ala Gly Asn Met Glu 115 120 125 Asn Gln Ala Thr Asp Ala Gly Glu Ser Ser Gln Pro Ala Asn Gln Pro 130 135 140 Asp Met Ala Asn Ala Ala Asp Gly Met Gln Gly Asp Asp Pro Ser Ala 145 150 155 160 Gly Gly Gln Asn Ala Gly Asn Thr Ala Ala Gln Gly Ala Asn Gln Ala 165 170 175 Gly Asn Asn Gln Ala Ala Gly Ser Ser Asp Pro Ile Pro Ala Ser Asn 180 185 190 Pro Ala Pro Ala Asn Gly Gly Ser Asn Phe Gly Arg Val Asp Leu Ala 195 200 205 Asn Gly Val Leu Ile Asp Gly Pro Ser Gln Asn Ile Thr Leu Thr His 210 215 220 Cys Lys Gly Asp Ser Cys Ser Gly Asn Asn Phe Leu Asp Glu Glu Val 225 230 235 240 Gln Leu Lys Ser Glu Phe Glu Lys Leu Ser Asp Ala Asp Lys Ile Ser 245 250 255 Asn Tyr Lys Lys Asp Gly Lys Asn Asp Lys Phe Val Gly Leu Val Ala 260 265 270 Asp Ser Val Gln Met Lys Gly Ile Asn Gln Tyr Ile Ile Phe Tyr Lys 275 280 285 Pro Lys Pro Thr Ser Phe Ala Arg Phe Arg Arg Ser Ala Arg Ser Arg 290 295 300 Arg Ser Leu Pro Ala Glu Met Pro Leu Ile Pro Val Asn Gln Ala Asp 305 310 315 320 Thr Leu Ile Val Asp Gly Glu Ala Val Ser Leu Thr Gly His Ser Gly 325 330 335 Asn Ile Phe Ala Pro Glu Gly Asn Tyr Arg Tyr Leu Thr Tyr Gly Ala 2013202593 05 Apr 2013 2013202593 05 Apr 2013 340 345 350 Glu Lys Leu Pro Gly Gly Ser Tyr Ala Leu Arg Val Gln Gly Glu Pro 355 360 365 Ala Lys Gly Glu Met Leu Ala Gly Ala Ala Val Tyr Asn Gly Glu Val 370 375 380 Leu His Phe His Thr Glu Asn Gly Arg Pro Tyr Pro Thr Arg Gly Arg 385 390 395 400 Phe Ala Ala Lys Val Asp Phe Gly Ser Lys Ser Val Asp Gly Ile Ile 405 410 415 Asp Ser Gly Asp Asp Leu His Met Gly Thr Gln Lys Phe Lys Ala Ala 420 425 430 Ile Asp Gly Asn Gly Phe Lys Gly Thr Trp Thr Glu Asn Gly Ser Gly 435 440 445 Asp Val Ser Gly Lys Phe Tyr Gly Pro Ala Gly Glu Glu Val Ala Gly 450 455 460 Lys Tyr Ser Tyr Arg Pro Thr Asp Ala Glu Lys Gly Gly Phe Gly Val 465 470 475 480 Phe Ala Gly Lys Lys Glu Gln Asp 485 <210> 4 <211> 364 <212> PRT <213> Neisseria meningitidis <400> 4 Met Ser Met Lys His Phe Pro Ser Lys Val Leu Thr Thr Ala Ile Leu 1 5 10 15 Ala Thr Phe Cys Ser Gly Ala Leu Ala Ala Thr Ser Asp Asp Asp Val 20 25 30 Lys Lys Ala Ala Thr Val Ala Ile Val Ala Ala Tyr Asn Asn Gly Gln 35 40 45 Glu Ile Asn Gly Phe Lys Ala Gly Glu Thr Ile Tyr Asp Ile Gly Glu 50 55 60 Asp Gly Thr Ile Thr Gln Lys Asp Ala Thr Ala Ala Asp Val Glu Ala 65 70 75 80 Asp Asp Phe Lys Gly Leu Gly Leu Lys Lys Val Val Thr Asn Leu Thr 85 90 95 Lys Thr Val Asn Glu Asn Lys Gln Asn Val Asp Ala Lys Val Lys Ala 100 105 110 Ala Glu Ser Glu Ile Glu Lys Leu Thr Thr Lys Leu Ala Asp Thr Asp 115 120 125 Ala Ala Leu Ala Asp Thr Asp Ala Ala Leu Asp Glu Thr Thr Asn Ala 130 135 140 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Leu Asn Lys Leu Gly Glu Asn Ile Thr Thr Phe Ala Glu Glu Thr Lys 145 150 155 160 Thr Asn Ile Val Lys Ile Asp Glu Lys Leu Glu Ala Val Ala Asp Thr 165 170 175 Val Asp Lys His Ala Glu Ala Phe Asn Asp Ile Ala Asp Ser Leu Asp 180 185 190 Glu Thr Asn Thr Lys Ala Asp Glu Ala Val Lys Thr Ala Asn Glu Ala 195 200 205 Lys Gln Thr Ala Glu Glu Thr Lys Gln Asn Val Asp Ala Lys Val Lys 210 215 220 Ala Ala Glu Thr Ala Ala Gly Lys Ala Glu Ala Ala Ala Gly Thr Ala 225 230 235 240 Asn Thr Ala Ala Asp Lys Ala Glu Ala Val Ala Ala Lys Val Thr Asp 245 250 255 Ile Lys Ala Asp Ile Ala Thr Asn Lys Ala Asp Ile Ala Lys Asn Ser 260 265 270 Ala Arg Ile Asp Ser Leu Asp Lys Asn Val Ala Asn Leu Arg Lys Glu 275 280 285 Thr Arg Gln Gly Leu Ala Glu Gln Ala Ala Leu Ser Gly Leu Phe Gln 290 295 300 Pro Tyr Asn Val Gly Arg Phe Asn Val Thr Ala Ala Val Gly Gly Tyr 305 310 315 320 Lys Ser Glu Ser Ala Val Ala Ile Gly Thr Gly Phe Arg Phe Thr Glu 325 330 335 Asn Phe Ala Ala Lys Ala Gly Val Ala Val Gly Thr Ser Ser Gly Ser 340 345 350 Ser Ala Ala Tyr His Val Gly Val Asn Tyr Glu Trp 355 360 <210> 5 <211> 174 <212> PRT <213> Neisseria meningitidis <400> 5 Met Lys Lys Ala Leu Ala Thr Leu Ile Ala Leu Ala Leu Pro Ala Ala 1 5 10 15 Ala Leu Ala Glu Gly Ala Ser Gly Phe Tyr Val Gln Ala Asp Ala Ala 20 25 30 His Ala Lys Ala Ser Ser Ser Leu Gly Ser Ala Lys Gly Phe Ser Pro 35 40 45 Arg Ile Ser Ala Gly Tyr Arg Ile Asn Asp Leu Arg Phe Ala Val Asp 50 55 60 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Tyr Thr Arg Tyr Lys Asn Tyr Lys Ala Pro Ser Thr Asp Phe Lys Leu 65 70 75 80 Tyr Ser Ile Gly Ala Ser Ala Ile Tyr Asp Phe Asp Thr Gln Ser Pro 85 90 95 Val Lys Pro Tyr Leu Gly Ala Arg Leu Ser Leu Asn Arg Ala Ser Val 100 105 110 Asp Leu Gly Gly Ser Asp Ser Phe Ser Gln Thr Ser Ile Gly Leu Gly 115 120 125 Val Leu Thr Gly Val Ser Tyr Ala Val Thr Pro Asn Val Asp Leu Asp 130 135 140 Ala Gly Tyr Arg Tyr Asn Tyr Ile Gly Lys Val Asn Thr Val Lys Asn 145 150 155 160 Val Arg Ser Gly Glu Leu Ser Ala Gly Val Arg Val Lys Phe 165 170 <210> 6 <211> 591 <212> PRT <213> Neisseria meningitidis <400> 6 Met Asn Lys Ile Tyr Arg Ile Ile Trp Asn Ser Ala Leu Asn Ala Trp 1 5 10 15 Val Val Val Ser Glu Leu Thr Arg Asn His Thr Lys Arg Ala Ser Ala 20 25 30 Thr Val Lys Thr Ala Val Leu Ala Thr Leu Leu Phe Ala Thr Val Gln 35 40 45 Ala Ser Ala Asn Asn Glu Glu Gln Glu Glu Asp Leu Tyr Leu Asp Pro 50 55 60 Val Gln Arg Thr Val Ala Val Leu Ile Val Asn Ser Asp Lys Glu Gly 65 70 75 80 Thr Gly Glu Lys Glu Lys Val Glu Glu Asn Ser Asp Trp Ala Val Tyr 85 90 95 Phe Asn Glu Lys Gly Val Leu Thr Ala Arg Glu Ile Thr Leu Lys Ala 100 105 110 Gly Asp Asn Leu Lys Ile Lys Gln Asn Gly Thr Asn Phe Thr Tyr Ser 115 120 125 Leu Lys Lys Asp Leu Thr Asp Leu Thr Ser Val Gly Thr Glu Lys Leu 130 135 140 Ser Phe Ser Ala Asn Gly Asn Lys Val Asn Ile Thr Ser Asp Thr Lys 145 150 155 160 Gly Leu Asn Phe Ala Lys Glu Thr Ala Gly Thr Asn Gly Asp Thr Thr 165 170 175 Val His Leu Asn Gly Ile Gly Ser Thr Leu Thr Asp Thr Leu Leu Asn 2013202593 05 Apr 2013 2013202593 05 Apr 2013 180 185 190 Thr Gly Ala Thr Thr Asn Val Thr Asn Asp Asn Val Thr Asp Asp Glu 195 200 205 Lys Lys Arg Ala Ala Ser Val Lys Asp Val Leu Asn Ala Gly Trp Asn 210 215 220 Ile Lys Gly Val Lys Pro Gly Thr Thr Ala Ser Asp Asn Val Asp Phe 225 230 235 240 Val Arg Thr Tyr Asp Thr Val Glu Phe Leu Ser Ala Asp Thr Lys Thr 245 250 255 Thr Thr Val Asn Val Glu Ser Lys Asp Asn Gly Lys Lys Thr Glu Val 260 265 270 Lys Ile Gly Ala Lys Thr Ser Val Ile Lys Glu Lys Asp Gly Lys Leu 275 280 285 Val Thr Gly Lys Asp Lys Gly Glu Asn Gly Ser Ser Thr Asp Glu Gly 290 295 300 Glu Gly Leu Val Thr Ala Lys Glu Val Ile Asp Ala Val Asn Lys Ala 305 310 315 320 Gly Trp Arg Met Lys Thr Thr Thr Ala Asn Gly Gln Thr Gly Gln Ala 325 330 335 Asp Lys Phe Glu Thr Val Thr Ser Gly Thr Asn Val Thr Phe Ala Ser 340 345 350 Gly Lys Gly Thr Thr Ala Thr Val Ser Lys Asp Asp Gln Gly Asn Ile 355 360 365 Thr Val Met Tyr Asp Val Asn Val Gly Asp Ala Leu Asn Val Asn Gln 370 375 380 Leu Gln Asn Ser Gly Trp Asn Leu Asp Ser Lys Ala Val Ala Gly Ser 385 390 395 400 Ser Gly Lys Val Ile Ser Gly Asn Val Ser Pro Ser Lys Gly Lys Met 405 410 415 Asp Glu Thr Val Asn Ile Asn Ala Gly Asn Asn Ile Glu Ile Thr Arg 420 425 430 Asn Gly Lys Asn Ile Asp Ile Ala Thr Ser Met Thr Pro Gln Phe Ser 435 440 445 Ser Val Ser Leu Gly Ala Gly Ala Asp Ala Pro Thr Leu Ser Val Asp 450 455 460 Gly Asp Ala Leu Asn Val Gly Ser Lys Lys Asp Asn Lys Pro Val Arg 465 470 475 480 Ile Thr Asn Val Ala Pro Gly Val Lys Glu Gly Asp Val Thr Asn Val 485 490 495 Ala Gln Leu Lys Gly Val Ala Gln Asn Leu Asn Asn Arg Ile Asp Asn 500 505 510 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Val Asp Gly Asn Ala Arg Ala Gly Ile Ala Gln Ala Ile Ala Thr Ala 515 520 525 Gly Leu Val Gln Ala Tyr Leu Pro Gly Lys Ser Met Met Ala Ile Gly 530 535 540 Gly Gly Thr Tyr Arg Gly Glu Ala Gly Tyr Ala Ile Gly Tyr Ser Ser 545 550 555 560 Ile Ser Asp Gly Gly Asn Trp Ile Ile Lys Gly Thr Ala Ser Gly Asn 565 570 575 Ser Arg Gly His Phe Gly Ala Ser Ala Ser Val Gly Tyr Gln Trp 580 585 590 <210> 7 <211> 1457 <212> PRT <213> Neisseria meningitidis <400> 7 Met Lys Thr Thr Asp Lys Arg Thr Thr Glu Thr His Arg Lys Ala Pro 1 5 10 15 Lys Thr Gly Arg Ile Arg Phe Ser Pro Ala Tyr Leu Ala Ile Cys Leu 20 25 30 Ser Phe Gly Ile Leu Pro Gln Ala Trp Ala Gly His Thr Tyr Phe Gly 35 40 45 Ile Asn Tyr Gln Tyr Tyr Arg Asp Phe Ala Glu Asn Lys Gly Lys Phe 50 55 60 Ala Val Gly Ala Lys Asp Ile Glu Val Tyr Asn Lys Lys Gly Glu Leu 65 70 75 80 Val Gly Lys Ser Met Thr Lys Ala Pro Met Ile Asp Phe Ser Val Val 85 90 95 Ser Arg Asn Gly Val Ala Ala Leu Val Gly Asp Gln Tyr Ile Val Ser 100 105 110 Val Ala His Asn Gly Gly Tyr Asn Asn Val Asp Phe Gly Ala Glu Gly 115 120 125 Arg Asn Pro Asp Gln His Arg Phe Thr Tyr Lys Ile Val Lys Arg Asn 130 135 140 Asn Tyr Lys Ala Gly Thr Lys Gly His Pro Tyr Gly Gly Asp Tyr His 145 150 155 160 Met Pro Arg Leu His Lys Phe Val Thr Asp Ala Glu Pro Val Glu Met 165 170 175 Thr Ser Tyr Met Asp Gly Arg Lys Tyr Ile Asp Gln Asn Asn Tyr Pro 180 185 190 Asp Arg Val Arg Ile Gly Ala Gly Arg Gln Tyr Trp Arg Ser Asp Glu 195 200 205 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Asp Glu Pro Asn Asn Arg Glu Ser Ser Tyr His Ile Ala Ser Ala Tyr 210 215 220 Ser Trp Leu Val Gly Gly Asn Thr Phe Ala Gln Asn Gly Ser Gly Gly 225 230 235 240 Gly Thr Val Asn Leu Gly Ser Glu Lys Ile Lys His Ser Pro Tyr Gly 245 250 255 Phe Leu Pro Thr Gly Gly Ser Phe Gly Asp Ser Gly Ser Pro Met Phe 260 265 270 Ile Tyr Asp Ala Gln Lys Gln Lys Trp Leu Ile Asn Gly Val Leu Gln 275 280 285 Thr Gly Asn Pro Tyr Ile Gly Lys Ser Asn Gly Phe Gln Leu Val Arg 290 295 300 Lys Asp Trp Phe Tyr Asp Glu Ile Phe Ala Gly Asp Thr His Ser Val 305 310 315 320 Phe Tyr Glu Pro Arg Gln Asn Gly Lys Tyr Ser Phe Asn Asp Asp Asn 325 330 335 Asn Gly Thr Gly Lys Ile Asn Ala Lys His Glu His Asn Ser Leu Pro 340 345 350 Asn Arg Leu Lys Thr Arg Thr Val Gln Leu Phe Asn Val Ser Leu Ser 355 360 365 Glu Thr Ala Arg Glu Pro Val Tyr His Ala Ala Gly Gly Val Asn Ser 370 375 380 Tyr Arg Pro Arg Leu Asn Asn Gly Glu Asn Ile Ser Phe Ile Asp Glu 385 390 395 400 Gly Lys Gly Glu Leu Ile Leu Thr Ser Asn Ile Asn Gln Gly Ala Gly 405 410 415 Gly Leu Tyr Phe Gln Gly Asp Phe Thr Val Ser Pro Glu Asn Asn Glu 420 425 430 Thr Trp Gln Gly Ala Gly Val His Ile Ser Glu Asp Ser Thr Val Thr 435 440 445 Trp Lys Val Asn Gly Val Ala Asn Asp Arg Leu Ser Lys Ile Gly Lys 450 455 460 Gly Thr Leu His Val Gln Ala Lys Gly Glu Asn Gln Gly Ser Ile Ser 465 470 475 480 Val Gly Asp Gly Thr Val Ile Leu Asp Gln Gln Ala Asp Asp Lys Gly 485 490 495 Lys Lys Gln Ala Phe Ser Glu Ile Gly Leu Val Ser Gly Arg Gly Thr 500 505 510 Val Gln Leu Asn Ala Asp Asn Gln Phe Asn Pro Asp Lys Leu Tyr Phe 515 520 525 Gly Phe Arg Gly Gly Arg Leu Asp Leu Asn Gly His Ser Leu Ser Phe 2013202593 05 Apr 2013 2013202593 05 Apr 2013 530 535 540 His Arg Ile Gln Asn Thr Asp Glu Gly Ala Met Ile Val Asn His Asn 545 550 555 560 Gln Asp Lys Glu Ser Thr Val Thr Ile Thr Gly Asn Lys Asp Ile Ala 565 570 575 Thr Thr Gly Asn Asn Asn Ser Leu Asp Ser Lys Lys Glu Ile Ala Tyr 580 585 590 Asn Gly Trp Phe Gly Glu Lys Asp Thr Thr Lys Thr Asn Gly Arg Leu 595 600 605 Asn Leu Val Tyr Gln Pro Ala Ala Glu Asp Arg Thr Leu Leu Leu Ser 610 615 620 Gly Gly Thr Asn Leu Asn Gly Asn Ile Thr Gln Thr Asn Gly Lys Leu 625 630 635 640 Phe Phe Ser Gly Arg Pro Thr Pro His Ala Tyr Asn His Leu Asn Asp 645 650 655 His Trp Ser Gln Lys Glu Gly Ile Pro Arg Gly Glu Ile Val Trp Asp 660 665 670 Asn Asp Trp Ile Asn Arg Thr Phe Lys Ala Glu Asn Phe Gln Ile Lys 675 680 685 Gly Gly Gln Ala Val Val Ser Arg Asn Val Ala Lys Val Lys Gly Asp 690 695 700 Trp His Leu Ser Asn His Ala Gln Ala Val Phe Gly Val Ala Pro His 705 710 715 720 Gln Ser His Thr Ile Cys Thr Arg Ser Asp Trp Thr Gly Leu Thr Asn 725 730 735 Cys Val Glu Lys Thr Ile Thr Asp Asp Lys Val Ile Ala Ser Leu Thr 740 745 750 Lys Thr Asp Ile Ser Gly Asn Val Asp Leu Ala Asp His Ala His Leu 755 760 765 Asn Leu Thr Gly Leu Ala Thr Leu Asn Gly Asn Leu Ser Ala Asn Gly 770 775 780 Asp Thr Arg Tyr Thr Val Ser His Asn Ala Thr Gln Asn Gly Asn Leu 785 790 795 800 Ser Leu Val Gly Asn Ala Gln Ala Thr Phe Asn Gln Ala Thr Leu Asn 805 810 815 Gly Asn Thr Ser Ala Ser Gly Asn Ala Ser Phe Asn Leu Ser Asp His 820 825 830 Ala Val Gln Asn Gly Ser Leu Thr Leu Ser Gly Asn Ala Lys Ala Asn 835 840 845 Val Ser His Ser Ala Leu Asn Gly Asn Val Ser Leu Ala Asp Lys Ala 850 855 860 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Val Phe His Phe Glu Ser Ser Arg Phe Thr Gly Gln Ile Ser Gly Gly 865 870 875 880 Lys Asp Thr Ala Leu His Leu Lys Asp Ser Glu Trp Thr Leu Pro Ser 885 890 895 Gly Thr Glu Leu Gly Asn Leu Asn Leu Asp Asn Ala Thr Ile Thr Leu 900 905 910 Asn Ser Ala Tyr Arg His Asp Ala Ala Gly Ala Gln Thr Gly Ser Ala 915 920 925 Thr Asp Ala Pro Arg Arg Arg Ser Arg Arg Ser Arg Arg Ser Leu Leu 930 935 940 Ser Val Thr Pro Pro Thr Ser Val Glu Ser Arg Phe Asn Thr Leu Thr 945 950 955 960 Val Asn Gly Lys Leu Asn Gly Gln Gly Thr Phe Arg Phe Met Ser Glu 965 970 975 Leu Phe Gly Tyr Arg Ser Asp Lys Leu Lys Leu Ala Glu Ser Ser Glu 980 985 990 Gly Thr Tyr Thr Leu Ala Val Asn Asn Thr Gly Asn Glu Pro Ala Ser 995 1000 1005 Leu Glu Gln Leu Thr Val Val Glu Gly Lys Asp Asn Lys Pro Leu Ser 1010 1015 1020 Glu Asn Leu Asn Phe Thr Leu Gln Asn Glu His Val Asp Ala Gly Ala 1025 1030 1035 1040 Trp Arg Tyr Gln Leu Ile Arg Lys Asp Gly Glu Phe Arg Leu His Asn 1045 1050 1055 Pro Val Lys Glu Gln Glu Leu Ser Asp Lys Leu Gly Lys Ala Glu Ala 1060 1065 1070 Lys Lys Gln Ala Glu Lys Asp Asn Ala Gln Ser Leu Asp Ala Leu Ile 1075 1080 1085 Ala Ala Gly Arg Asp Ala Val Glu Lys Thr Glu Ser Val Ala Glu Pro 1090 1095 1100 Ala Arg Gln Ala Gly Gly Glu Asn Val Gly Ile Met Gln Ala Glu Glu 1105 1110 1115 1120 Glu Lys Lys Arg Val Gln Ala Asp Lys Asp Thr Ala Leu Ala Lys Gln 1125 1130 1135 Arg Glu Ala Glu Thr Arg Pro Ala Thr Thr Ala Phe Pro Arg Ala Arg 1140 1145 1150 Arg Ala Arg Arg Asp Leu Pro Gln Leu Gln Pro Gln Pro Gln Pro Gln 1155 1160 1165 Pro Gln Arg Asp Leu Ile Ser Arg Tyr Ala Asn Ser Gly Leu Ser Glu 1170 1175 1180 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Phe Ser Ala Thr Leu Asn Ser Val Phe Ala Val Gln Asp Glu Leu Asp 1185 1190 1195 1200 Arg Val Phe Ala Glu Asp Arg Arg Asn Ala Val Trp Thr Ser Gly Ile 1205 1210 1215 Arg Asp Thr Lys His Tyr Arg Ser Gln Asp Phe Arg Ala Tyr Arg Gln 1220 1225 1230 Gln Thr Asp Leu Arg Gln Ile Gly Met Gln Lys Asn Leu Gly Ser Gly 1235 1240 1245 Arg Val Gly Ile Leu Phe Ser His Asn Arg Thr Glu Asn Thr Phe Asp 1250 1255 1260 Asp Gly Ile Gly Asn Ser Ala Arg Leu Ala His Gly Ala Val Phe Gly 1265 1270 1275 1280 Gln Tyr Gly Ile Asp Arg Phe Tyr Ile Gly Ile Ser Ala Gly Ala Gly 1285 1290 1295 Phe Ser Ser Gly Ser Leu Ser Asp Gly Ile Gly Gly Lys Ile Arg Arg 1300 1305 1310 Arg Val Leu His Tyr Gly Ile Gln Ala Arg Tyr Arg Ala Gly Phe Gly 1315 1320 1325 Gly Phe Gly Ile Glu Pro His Ile Gly Ala Thr Arg Tyr Phe Val Gln 1330 1335 1340 Lys Ala Asp Tyr Arg Tyr Glu Asn Val Asn Ile Ala Thr Pro Gly Leu 1345 1350 1355 1360 Ala Phe Asn Arg Tyr Arg Ala Gly Ile Lys Ala Asp Tyr Ser Phe Lys 1365 1370 1375 Pro Ala Gln His Ile Ser Ile Thr Pro Tyr Leu Ser Leu Ser Tyr Thr 1380 1385 1390 Asp Ala Ala Ser Gly Lys Val Arg Thr Arg Val Asn Thr Ala Val Leu 1395 1400 1405 Ala Gln Asp Phe Gly Lys Thr Arg Ser Ala Glu Trp Gly Val Asn Ala 1410 1415 1420 Glu Ile Lys Gly Phe Thr Leu Ser Leu His Ala Ala Ala Ala Lys Gly 1425 1430 1435 1440 Pro Gln Leu Glu Ala Gln His Ser Ala Gly Ile Lys Leu Gly Tyr Arg 1445 1450 1455 Trp <210> 8 <211> 797 <212> PRT <213> Neisseria meningitidis <400> 8 Met Lys Leu Lys Gln Ile Ala Ser Ala Leu Met Met Leu Gly Ile Ser 2013202593 05 Apr 2013 2013202593 05 Apr 2013 1 5 10 15 Pro Leu Ala Leu Ala Asp Phe Thr Ile Gln Asp Ile Arg Val Glu Gly 20 25 30 Leu Gln Arg Thr Glu Pro Ser Thr Val Phe Asn Tyr Leu Pro Val Lys 35 40 45 Val Gly Asp Thr Tyr Asn Asp Thr His Gly Ser Ala Ile Ile Lys Ser 50 55 60 Leu Tyr Ala Thr Gly Phe Phe Asp Asp Val Arg Val Glu Thr Ala Asp 65 70 75 80 Gly Gln Leu Leu Leu Thr Val Ile Glu Arg Pro Thr Ile Gly Ser Leu 85 90 95 Asn Ile Thr Gly Ala Lys Met Leu Gln Asn Asp Ala Ile Lys Lys Asn 100 105 110 Leu Glu Ser Phe Gly Leu Ala Gln Ser Gln Tyr Phe Asn Gln Ala Thr 115 120 125 Leu Asn Gln Ala Val Ala Gly Leu Lys Glu Glu Tyr Leu Gly Arg Gly 130 135 140 Lys Leu Asn Ile Gln Ile Thr Pro Lys Val Thr Lys Leu Ala Arg Asn 145 150 155 160 Arg Val Asp Ile Asp Ile Thr Ile Asp Glu Gly Lys Ser Ala Lys Ile 165 170 175 Thr Asp Ile Glu Phe Glu Gly Asn Gln Val Tyr Ser Asp Arg Lys Leu 180 185 190 Met Arg Gln Met Ser Leu Thr Glu Gly Gly Ile Trp Thr Trp Leu Thr 195 200 205 Arg Ser Asn Gln Phe Asn Glu Gln Lys Phe Ala Gln Asp Met Glu Lys 210 215 220 Val Thr Asp Phe Tyr Gln Asn Asn Gly Tyr Phe Asp Phe Arg Ile Leu 225 230 235 240 Asp Thr Asp Ile Gln Thr Asn Glu Asp Lys Thr Lys Gln Thr Ile Lys 245 250 255 Ile Thr Val His Glu Gly Gly Arg Phe Arg Trp Gly Lys Val Ser Ile 260 265 270 Glu Gly Asp Thr Asn Glu Val Pro Lys Ala Glu Leu Glu Lys Leu Leu 275 280 285 Thr Met Lys Pro Gly Lys Trp Tyr Glu Arg Gln Gln Met Thr Ala Val 290 295 300 Leu Gly Glu Ile Gln Asn Arg Met Gly Ser Ala Gly Tyr Ala Tyr Ser 305 310 315 320 Glu Ile Ser Val Gln Pro Leu Pro Asn Ala Glu Thr Lys Thr Val Asp 325 330 335 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Phe Val Leu His Ile Glu Pro Gly Arg Lys Ile Tyr Val Asn Glu Ile 340 345 350 His Ile Thr Gly Asn Asn Lys Thr Arg Asp Glu Val Val Arg Arg Glu 355 360 365 Leu Arg Gln Met Glu Ser Ala Pro Tyr Asp Thr Ser Lys Leu Gln Arg 370 375 380 Ser Lys Glu Arg Val Glu Leu Leu Gly Tyr Phe Asp Asn Val Gln Phe 385 390 395 400 Asp Ala Val Pro Leu Ala Gly Thr Pro Asp Lys Val Asp Leu Asn Met 405 410 415 Ser Leu Thr Glu Arg Ser Thr Gly Ser Leu Asp Leu Ser Ala Gly Trp 420 425 430 Val Gln Asp Thr Gly Leu Val Met Ser Ala Gly Val Ser Gln Asp Asn 435 440 445 Leu Phe Gly Thr Gly Lys Ser Ala Ala Leu Arg Ala Ser Arg Ser Lys 450 455 460 Thr Thr Leu Asn Gly Ser Leu Ser Phe Thr Asp Pro Tyr Phe Thr Ala 465 470 475 480 Asp Gly Val Ser Leu Gly Tyr Asp Val Tyr Gly Lys Ala Phe Asp Pro 485 490 495 Arg Lys Ala Ser Thr Ser Ile Lys Gln Tyr Lys Thr Thr Thr Ala Gly 500 505 510 Ala Gly Ile Arg Met Ser Val Pro Val Thr Glu Tyr Asp Arg Val Asn 515 520 525 Phe Gly Leu Val Ala Glu His Leu Thr Val Asn Thr Tyr Asn Lys Ala 530 535 540 Pro Lys His Tyr Ala Asp Phe Ile Lys Lys Tyr Gly Lys Thr Asp Gly 545 550 555 560 Thr Asp Gly Ser Phe Lys Gly Trp Leu Tyr Lys Gly Thr Val Gly Trp 565 570 575 Gly Arg Asn Lys Thr Asp Ser Ala Leu Trp Pro Thr Arg Gly Tyr Leu 580 585 590 Thr Gly Val Asn Ala Glu Ile Ala Leu Pro Gly Ser Lys Leu Gln Tyr 595 600 605 Tyr Ser Ala Thr His Asn Gln Thr Trp Phe Phe Pro Leu Ser Lys Thr 610 615 620 Phe Thr Leu Met Leu Gly Gly Glu Val Gly Ile Ala Gly Gly Tyr Gly 625 630 635 640 Arg Thr Lys Glu Ile Pro Phe Phe Glu Asn Phe Tyr Gly Gly Gly Leu 645 650 655 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Gly Ser Val Arg Gly Tyr Glu Ser Gly Thr Leu Gly Pro Lys Val Tyr 660 665 670 Asp Glu Tyr Gly Glu Lys Ile Ser Tyr Gly Gly Asn Lys Lys Ala Asn 675 680 685 Val Ser Ala Glu Leu Leu Phe Pro Met Pro Gly Ala Lys Asp Ala Arg 690 695 700 Thr Val Arg Leu Ser Leu Phe Ala Asp Ala Gly Ser Val Trp Asp Gly 705 710 715 720 Lys Thr Tyr Asp Asp Asn Ser Ser Ser Ala Thr Gly Gly Arg Val Gln 725 730 735 Asn Ile Tyr Gly Ala Gly Asn Thr His Lys Ser Thr Phe Thr Asn Glu 740 745 750 Leu Arg Tyr Ser Ala Gly Gly Ala Val Thr Trp Leu Ser Pro Leu Gly 755 760 765 Pro Met Lys Phe Ser Tyr Ala Tyr Pro Leu Lys Lys Lys Pro Glu Asp 770 775 780 Glu Ile Gln Arg Phe Gln Phe Gln Leu Gly Thr Thr Phe 785 790 795 <210> 9 <211> 248 <212> PRT <213> Neisseria meningitidis <400> 9 Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro 1 5 10 15 Leu Asp His Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser 20 25 30 Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys 35 40 45 Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp 50 55 60 Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln 65 70 75 80 Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His 85 90 95 Ser Ala Leu Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His 100 105 110 Ser Gly Lys Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala 115 120 125 Gly Glu His Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr 130 135 140 Tyr Arg Gly Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr 2013202593 05 Apr 2013 2013202593 05 Apr 2013 145 150 155 160 Tyr Thr Ile Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His 165 170 175 Leu Lys Ser Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys 180 185 190 Pro Asp Gly Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn 195 200 205 Gln Ala Glu Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala 210 215 220 Gln Glu Val Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg 225 230 235 240 His Ile Gly Leu Ala Ala Lys Gln 245 <210> 10 <211> 247 <212> PRT <213> Neisseria meningitidis <400> 10 Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro 1 5 10 15 Leu Asp His Lys Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser 20 25 30 Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys 35 40 45 Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp 50 55 60 Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln 65 70 75 80 Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His 85 90 95 Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys 100 105 110 Ile Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly 115 120 125 Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr 130 135 140 His Gly Lys Ala Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr 145 150 155 160 Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu 165 170 175 Lys Thr Pro Glu Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala 180 185 190 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser 195 200 205 Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln 210 215 220 Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu 225 230 235 240 Ile Gly Ile Ala Gly Lys Gln 245 <210> 11 <211> 250 <212> PRT <213> Neisseria meningitidis <400> 11 Val Ala Ala Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro 1 5 10 15 Leu Asp His Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser 20 25 30 Ile Pro Gln Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys 35 40 45 Thr Phe Lys Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu 50 55 60 Lys Asn Asp Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val 65 70 75 80 Asp Gly Gln Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys 85 90 95 Gln Asn His Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn 100 105 110 Pro Asp Lys Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser 115 120 125 Gly Leu Gly Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys 130 135 140 Ala Glu Tyr His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg 145 150 155 160 Leu His Tyr Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile 165 170 175 Glu His Leu Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu 180 185 190 Leu Lys Ala Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg 195 200 205 Tyr Gly Ser Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp 210 215 220 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Arg Ala Gln Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys 225 230 235 240 Val His Glu Ile Gly Ile Ala Gly Lys Gln 245 250 <210> 12 <211> 792 <212> PRT <213> Neisseria meningitidis <400> 12 Met Lys Pro Leu Gln Met Leu Pro Ile Ala Ala Leu Val Gly Ser Ile 1 5 10 15 Phe Gly Asn Pro Val Leu Ala Ala Asp Glu Ala Ala Thr Glu Thr Thr 20 25 30 Pro Val Lys Ala Glu Ile Lys Ala Val Arg Val Lys Gly Gln Arg Asn 35 40 45 Ala Pro Ala Ala Val Glu Arg Val Asn Leu Asn Arg Ile Lys Gln Glu 50 55 60 Met Ile Arg Asp Asn Lys Asp Leu Val Arg Tyr Ser Thr Asp Val Gly 65 70 75 80 Leu Ser Asp Ser Gly Arg His Gln Lys Gly Phe Ala Val Arg Gly Val 85 90 95 Glu Gly Asn Arg Val Gly Val Ser Ile Asp Gly Val Asn Leu Pro Asp 100 105 110 Ser Glu Glu Asn Ser Leu Tyr Ala Arg Tyr Gly Asn Phe Asn Ser Ser 115 120 125 Arg Leu Ser Ile Asp Pro Glu Leu Val Arg Asn Ile Glu Ile Val Lys 130 135 140 Gly Ala Asp Ser Phe Asn Thr Gly Ser Gly Ala Leu Gly Gly Gly Val 145 150 155 160 Asn Tyr Gln Thr Leu Gln Gly Arg Asp Leu Leu Leu Asp Asp Arg Gln 165 170 175 Phe Gly Val Met Met Lys Asn Gly Tyr Ser Thr Arg Asn Arg Glu Trp 180 185 190 Thr Asn Thr Leu Gly Phe Gly Val Ser Asn Asp Arg Val Asp Ala Ala 195 200 205 Leu Leu Tyr Ser Gln Arg Arg Gly His Glu Thr Glu Ser Ala Gly Asn 210 215 220 Arg Gly Tyr Ala Val Glu Gly Glu Gly Ser Gly Ala Asn Ile Arg Gly 225 230 235 240 Ser Ala Arg Gly Ile Pro Asp Ser Ser Lys His Lys Tyr Asn His His 245 250 255 Ala Leu Gly Lys Ile Ala Tyr Gln Ile Asn Asp Asn His Arg Ile Gly 2013202593 05 Apr 2013 2013202593 05 Apr 2013 260 265 270 Ala Ser Leu Asn Gly Gln Gln Gly His Asn Tyr Thr Val Glu Glu Ser 275 280 285 Tyr Asn Leu Thr Ala Ser Ser Trp Arg Glu Ala Asp Asp Val Asn Arg 290 295 300 Arg Arg Asn Ala Asn Leu Phe Tyr Glu Trp Met Pro Asp Ser Asn Trp 305 310 315 320 Leu Ser Ser Leu Lys Ala Asp Phe Asp Tyr Gln Lys Thr Lys Val Ala 325 330 335 Ala Val Asn Asn Lys Gly Ser Phe Pro Met Asp Tyr Ser Thr Trp Thr 340 345 350 Arg Asn Tyr Asn Gln Lys Asp Leu Asp Glu Ile Tyr Asn Arg Ser Met 355 360 365 Asp Thr Arg Phe Lys Arg Phe Thr Leu Arg Leu Asp Ser His Pro Leu 370 375 380 Gln Leu Gly Gly Gly Arg His Arg Leu Ser Phe Lys Thr Phe Val Ser 385 390 395 400 Arg Arg Asp Phe Glu Asn Leu Asn Arg Asp Asp Tyr Tyr Phe Ser Gly 405 410 415 Arg Val Val Arg Thr Thr Ser Ser Ile Gln His Pro Val Lys Thr Thr 420 425 430 Asn Tyr Gly Phe Ser Leu Ser Asp Gln Ile Gln Trp Asn Asp Val Phe 435 440 445 Ser Ser Arg Ala Gly Ile Arg Tyr Asp His Thr Lys Met Thr Pro Gln 450 455 460 Glu Leu Asn Ala Glu Cys His Ala Cys Asp Lys Thr Pro Pro Ala Ala 465 470 475 480 Asn Thr Tyr Lys Gly Trp Ser Gly Phe Val Gly Leu Ala Ala Gln Leu 485 490 495 Asn Gln Ala Trp Arg Val Gly Tyr Asp Ile Thr Ser Gly Tyr Arg Val 500 505 510 Pro Asn Ala Ser Glu Val Tyr Phe Thr Tyr Asn His Gly Ser Gly Asn 515 520 525 Trp Leu Pro Asn Pro Asn Leu Lys Ala Glu Arg Ser Thr Thr His Thr 530 535 540 Leu Ser Leu Gln Gly Arg Ser Glu Lys Gly Met Leu Asp Ala Asn Leu 545 550 555 560 Tyr Gln Ser Asn Tyr Arg Asn Phe Leu Ser Glu Glu Gln Lys Leu Thr 565 570 575 Thr Ser Gly Thr Pro Gly Cys Thr Glu Glu Asn Ala Tyr Tyr Gly Ile 580 585 590 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Cys Ser Asp Pro Tyr Lys Glu Lys Leu Asp Trp Gln Met Lys Asn Ile 595 600 605 Asp Lys Ala Arg Ile Arg Gly Ile Glu Leu Thr Gly Arg Leu Asn Val 610 615 620 Asp Lys Val Ala Ser Phe Val Pro Glu Gly Trp Lys Leu Phe Gly Ser 625 630 635 640 Leu Gly Tyr Ala Lys Ser Lys Leu Ser Gly Asp Asn Ser Leu Leu Ser 645 650 655 Thr Gln Pro Leu Lys Val Ile Ala Gly Ile Asp Tyr Glu Ser Pro Ser 660 665 670 Glu Lys Trp Gly Val Phe Ser Arg Leu Thr Tyr Leu Gly Ala Lys Lys 675 680 685 Val Lys Asp Ala Gln Tyr Thr Val Tyr Glu Asn Lys Gly Trp Gly Thr 690 695 700 Pro Leu Gln Lys Lys Val Lys Asp Tyr Pro Trp Leu Asn Lys Ser Ala 705 710 715 720 Tyr Val Phe Asp Met Tyr Gly Phe Tyr Lys Pro Ala Lys Asn Leu Thr 725 730 735 Leu Arg Ala Gly Val Tyr Asn Leu Phe Asn Arg Lys Tyr Thr Thr Trp 740 745 750 Asp Ser Leu Arg Gly Leu Tyr Ser Tyr Ser Thr Thr Asn Ala Val Asp 755 760 765 Arg Asp Gly Lys Gly Leu Asp Arg Tyr Arg Ala Pro Gly Arg Asn Tyr 770 775 780 Ala Val Ser Leu Glu Trp Lys Phe 785 790 <210> 13 <211> 644 <212> PRT <213> Neisseria meningitidis <400> 13 Met Ala Ser Pro Asp Val Lys Ser Ala Asp Thr Leu Ser Lys Pro Ala 1 5 10 15 Ala Pro Val Val Ser Glu Lys Glu Thr Glu Ala Lys Glu Asp Ala Pro 20 25 30 Gln Ala Gly Ser Gln Gly Gln Gly Ala Pro Ser Ala Gln Gly Gly Gln 35 40 45 Asp Met Ala Ala Val Ser Glu Glu Asn Thr Gly Asn Gly Gly Ala Ala 50 55 60 Ala Thr Asp Lys Pro Lys Asn Glu Asp Glu Gly Ala Gln Asn Asp Met 65 70 75 80 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Pro Gln Asn Ala Ala Asp Thr Asp Ser Leu Thr Pro Asn His Thr Pro 85 90 95 Ala Ser Asn Met Pro Ala Gly Asn Met Glu Asn Gln Ala Pro Asp Ala 100 105 110 Gly Glu Ser Glu Gln Pro Ala Asn Gln Pro Asp Met Ala Asn Thr Ala 115 120 125 Asp Gly Met Gln Gly Asp Asp Pro Ser Ala Gly Gly Glu Asn Ala Gly 130 135 140 Asn Thr Ala Ala Gln Gly Thr Asn Gln Ala Glu Asn Asn Gln Thr Ala 145 150 155 160 Gly Ser Gln Asn Pro Ala Ser Ser Thr Asn Pro Ser Ala Thr Asn Ser 165 170 175 Gly Gly Asp Phe Gly Arg Thr Asn Val Gly Asn Ser Val Val Ile Asp 180 185 190 Gly Pro Ser Gln Asn Ile Thr Leu Thr His Cys Lys Gly Asp Ser Cys 195 200 205 Ser Gly Asn Asn Phe Leu Asp Glu Glu Val Gln Leu Lys Ser Glu Phe 210 215 220 Glu Lys Leu Ser Asp Ala Asp Lys Ile Ser Asn Tyr Lys Lys Asp Gly 225 230 235 240 Lys Asn Asp Gly Lys Asn Asp Lys Phe Val Gly Leu Val Ala Asp Ser 245 250 255 Val Gln Met Lys Gly Ile Asn Gln Tyr Ile Ile Phe Tyr Lys Pro Lys 260 265 270 Pro Thr Ser Phe Ala Arg Phe Arg Arg Ser Ala Arg Ser Arg Arg Ser 275 280 285 Leu Pro Ala Glu Met Pro Leu Ile Pro Val Asn Gln Ala Asp Thr Leu 290 295 300 Ile Val Asp Gly Glu Ala Val Ser Leu Thr Gly His Ser Gly Asn Ile 305 310 315 320 Phe Ala Pro Glu Gly Asn Tyr Arg Tyr Leu Thr Tyr Gly Ala Glu Lys 325 330 335 Leu Pro Gly Gly Ser Tyr Ala Leu Arg Val Gln Gly Glu Pro Ser Lys 340 345 350 Gly Glu Met Leu Ala Gly Thr Ala Val Tyr Asn Gly Glu Val Leu His 355 360 365 Phe His Thr Glu Asn Gly Arg Pro Ser Pro Ser Arg Gly Arg Phe Ala 370 375 380 Ala Lys Val Asp Phe Gly Ser Lys Ser Val Asp Gly Ile Ile Asp Ser 385 390 395 400 Gly Asp Gly Leu His Met Gly Thr Gln Lys Phe Lys Ala Ala Ile Asp 2013202593 05 Apr 2013 2013202593 05 Apr 2013 405 410 415 Gly Asn Gly Phe Lys Gly Thr Trp Thr Glu Asn Gly Gly Gly Asp Val 420 425 430 Ser Gly Lys Phe Tyr Gly Pro Ala Gly Glu Glu Val Ala Gly Lys Tyr 435 440 445 Ser Tyr Arg Pro Thr Asp Ala Glu Lys Gly Gly Phe Gly Val Phe Ala 450 455 460 Gly Lys Lys Glu Gln Asp Gly Ser Gly Gly Gly Gly Ala Thr Tyr Lys 465 470 475 480 Val Asp Glu Tyr His Ala Asn Ala Arg Phe Ala Ile Asp His Phe Asn 485 490 495 Thr Ser Thr Asn Val Gly Gly Phe Tyr Gly Leu Thr Gly Ser Val Glu 500 505 510 Phe Asp Gln Ala Lys Arg Asp Gly Lys Ile Asp Ile Thr Ile Pro Val 515 520 525 Ala Asn Leu Gln Ser Gly Ser Gln His Phe Thr Asp His Leu Lys Ser 530 535 540 Ala Asp Ile Phe Asp Ala Ala Gln Tyr Pro Asp Ile Arg Phe Val Ser 545 550 555 560 Thr Lys Phe Asn Phe Asn Gly Lys Lys Leu Val Ser Val Asp Gly Asn 565 570 575 Leu Thr Met His Gly Lys Thr Ala Pro Val Lys Leu Lys Ala Glu Lys 580 585 590 Phe Asn Cys Tyr Gln Ser Pro Met Ala Lys Thr Glu Val Cys Gly Gly 595 600 605 Asp Phe Ser Thr Thr Ile Asp Arg Thr Lys Trp Gly Val Asp Tyr Leu 610 615 620 Val Asn Val Gly Met Thr Lys Ser Val Arg Ile Asp Ile Gln Ile Glu 625 630 635 640 Ala Ala Lys Gln <210> 14 <211> 434 <212> PRT <213> Neisseria meningitidis <400> 14 Met Val Ser Ala Val Ile Gly Ser Ala Ala Val Gly Ala Lys Ser Ala 1 5 10 15 Val Asp Arg Arg Thr Thr Gly Ala Gln Thr Asp Asp Asn Val Met Ala 20 25 30 Leu Arg Ile Glu Thr Thr Ala Arg Ser Tyr Leu Arg Gln Asn Asn Gln 35 40 45 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Thr Lys Gly Tyr Thr Pro Gln Ile Ser Val Val Gly Tyr Asp Arg His 50 55 60 Leu Leu Leu Leu Gly Gln Val Ala Thr Glu Gly Glu Lys Gln Phe Val 65 70 75 80 Gly Gln Ile Ala Arg Ser Glu Gln Ala Ala Glu Gly Val Tyr Asn Tyr 85 90 95 Ile Thr Val Ala Ser Leu Pro Arg Thr Ala Gly Asp Ile Ala Gly Asp 100 105 110 Thr Trp Asn Thr Ser Lys Val Arg Ala Thr Leu Leu Gly Ile Ser Pro 115 120 125 Ala Thr Arg Ala Arg Val Lys Ile Val Thr Tyr Gly Asn Val Thr Tyr 130 135 140 Val Met Gly Ile Leu Thr Pro Glu Glu Gln Ala Gln Ile Thr Gln Lys 145 150 155 160 Val Ser Thr Thr Val Gly Val Gln Lys Val Ile Thr Leu Tyr Gln Asn 165 170 175 Tyr Val Gln Arg Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly 180 185 190 Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys 195 200 205 Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys 210 215 220 Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp 225 230 235 240 Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp 245 250 255 Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser 260 265 270 Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe 275 280 285 Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys Met Val Ala 290 295 300 Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His Thr Ser Phe 305 310 315 320 Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr Arg Gly Thr Ala Phe 325 330 335 Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Ala 340 345 350 Ala Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser Pro Glu Leu 355 360 365 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly Lys Arg His 370 375 380 Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu Lys Gly Ser 385 390 395 400 Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val Ala Gly Ser 405 410 415 Ala Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly Leu Ala Ala 420 425 430 Lys Gln <210> 15 <211> 350 <212> PRT <213> Neisseria meningitidis <400> 15 Met Lys His Phe Pro Ser Lys Val Leu Thr Thr Ala Ile Leu Ala Thr 1 5 10 15 Phe Cys Ser Gly Ala Leu Ala Ala Thr Asn Asp Asp Asp Val Lys Lys 20 25 30 Ala Ala Thr Val Ala Ile Ala Ala Ala Tyr Asn Asn Gly Gln Glu Ile 35 40 45 Asn Gly Phe Lys Ala Gly Glu Thr Ile Tyr Asp Ile Asp Glu Asp Gly 50 55 60 Thr Ile Thr Lys Lys Asp Ala Thr Ala Ala Asp Val Glu Ala Asp Asp 65 70 75 80 Phe Lys Gly Leu Gly Leu Lys Lys Val Val Thr Asn Leu Thr Lys Thr 85 90 95 Val Asn Glu Asn Lys Gln Asn Val Asp Ala Lys Val Lys Ala Ala Glu 100 105 110 Ser Glu Ile Glu Lys Leu Thr Thr Lys Leu Ala Asp Thr Asp Ala Ala 115 120 125 Leu Ala Asp Thr Asp Ala Ala Leu Asp Ala Thr Thr Asn Ala Leu Asn 130 135 140 Lys Leu Gly Glu Asn Ile Thr Thr Phe Ala Glu Glu Thr Lys Thr Asn 145 150 155 160 Ile Val Lys Ile Asp Glu Lys Leu Glu Ala Val Ala Asp Thr Val Asp 165 170 175 Lys His Ala Glu Ala Phe Asn Asp Ile Ala Asp Ser Leu Asp Glu Thr 180 185 190 Asn Thr Lys Ala Asp Glu Ala Val Lys Thr Ala Asn Glu Ala Lys Gln 195 200 205 Thr Ala Glu Glu Thr Lys Gln Asn Val Asp Ala Lys Val Lys Ala Ala 2013202593 05 Apr 2013 2013202593 05 Apr 2013 210 215 220 Glu Thr Ala Ala Gly Lys Ala Glu Ala Ala Ala Gly Thr Ala Asn Thr 225 230 235 240 Ala Ala Asp Lys Ala Glu Ala Val Ala Ala Lys Val Thr Asp Ile Lys 245 250 255 Ala Asp Ile Ala Thr Asn Lys Asp Asn Ile Ala Lys Lys Ala Asn Ser 260 265 270 Ala Asp Val Tyr Thr Arg Glu Glu Ser Asp Ser Lys Phe Val Arg Ile 275 280 285 Asp Gly Leu Asn Ala Thr Thr Glu Lys Leu Asp Thr Arg Leu Ala Ser 290 295 300 Ala Glu Lys Ser Ile Ala Asp His Asp Thr Arg Leu Asn Gly Leu Asp 305 310 315 320 Lys Thr Val Ser Asp Leu Arg Lys Glu Thr Arg Gln Gly Leu Ala Glu 325 330 335 Gln Ala Ala Leu Ser Gly Leu Phe Gln Pro Tyr Asn Val Gly 340 345 350 <210> 16 <211> 249 <212> PRT <213> Neisseria meningitidis <400> 16 Met Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala 1 5 10 15 Pro Leu Asp His Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln 20 25 30 Ser Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu 35 40 45 Lys Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn 50 55 60 Asp Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly 65 70 75 80 Gln Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser 85 90 95 His Ser Ala Leu Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu 100 105 110 His Ser Gly Lys Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile 115 120 125 Ala Gly Glu His Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala 130 135 140 Thr Tyr His Gly Lys Ala Phe Gly Ser Asp Asp Pro Asn Gly Arg Leu 145 150 155 160 2013202593 05 Apr 2013 2013202593 05 Apr 2013 His Tyr Thr Ile Asp Phe Ala Ala Lys Gln Gly Tyr Gly Arg Ile Glu 165 170 175 His Leu Lys Thr Pro Glu Gln Asn Val Asp Leu Ala Ala Ala Asp Ile 180 185 190 Lys Pro Asp Gly Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr 195 200 205 Asn Gln Ala Glu Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys 210 215 220 Ala Gln Glu Val Ala Gly Ser Ala Glu Val Lys Ile Gly Glu Gly Ile 225 230 235 240 Arg His Ile Gly Leu Ala Ala Lys Gln 245 <210> 17 <211> 776 <212> PRT <213> Neisseria meningitidis <400> 17 Met Gly Pro Asp Ser Asp Arg Leu Gln Gln Arg Arg Val Ala Ala Asp 1 5 10 15 Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys 20 25 30 Asp Lys Ser Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn 35 40 45 Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn 50 55 60 Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg 65 70 75 80 Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu 85 90 95 Glu Ser Gly Glu Phe Gln Ile Tyr Lys Gln Asp His Ser Ala Val Val 100 105 110 Ala Leu Gln Ile Glu Lys Ile Asn Asn Pro Asp Lys Ile Asp Ser Leu 115 120 125 Ile Asn Gln Arg Ser Phe Leu Val Ser Gly Leu Gly Gly Glu His Thr 130 135 140 Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr His Gly Lys Ala 145 150 155 160 Phe Ser Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe 165 170 175 Ala Ala Lys Gln Gly His Gly Lys Ile Glu His Leu Lys Thr Pro Glu 180 185 190 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Gln Asn Val Glu Leu Ala Ala Ala Glu Leu Lys Ala Asp Glu Lys Ser 195 200 205 His Ala Val Ile Leu Gly Asp Thr Arg Tyr Gly Ser Glu Glu Lys Gly 210 215 220 Thr Tyr His Leu Ala Leu Phe Gly Asp Arg Ala Gln Glu Ile Ala Gly 225 230 235 240 Ser Ala Thr Val Lys Ile Gly Glu Lys Val His Glu Ile Gly Ile Ala 245 250 255 Gly Lys Gln Gly Ser Gly Pro Asp Ser Asp Arg Leu Gln Gln Arg Arg 260 265 270 Val Ala Ala Asp Ile Gly Thr Gly Leu Ala Asp Ala Leu Thr Ala Pro 275 280 285 Leu Asp His Lys Asp Lys Gly Leu Lys Ser Leu Thr Leu Glu Asp Ser 290 295 300 Ile Pro Gln Asn Gly Thr Leu Thr Leu Ser Ala Gln Gly Ala Glu Lys 305 310 315 320 Thr Phe Lys Ala Gly Asp Lys Asp Asn Ser Leu Asn Thr Gly Lys Leu 325 330 335 Lys Asn Asp Lys Ile Ser Arg Phe Asp Phe Val Gln Lys Ile Glu Val 340 345 350 Asp Gly Gln Thr Ile Thr Leu Ala Ser Gly Glu Phe Gln Ile Tyr Lys 355 360 365 Gln Asn His Ser Ala Val Val Ala Leu Gln Ile Glu Lys Ile Asn Asn 370 375 380 Pro Asp Lys Thr Asp Ser Leu Ile Asn Gln Arg Ser Phe Leu Val Ser 385 390 395 400 Gly Leu Gly Gly Glu His Thr Ala Phe Asn Gln Leu Pro Gly Gly Lys 405 410 415 Ala Glu Tyr His Gly Lys Ala Phe Ser Ser Asp Asp Pro Asn Gly Arg 420 425 430 Leu His Tyr Ser Ile Asp Phe Thr Lys Lys Gln Gly Tyr Gly Arg Ile 435 440 445 Glu His Leu Lys Thr Leu Glu Gln Asn Val Glu Leu Ala Ala Ala Glu 450 455 460 Leu Lys Ala Asp Glu Lys Ser His Ala Val Ile Leu Gly Asp Thr Arg 465 470 475 480 Tyr Gly Ser Glu Glu Lys Gly Thr Tyr His Leu Ala Leu Phe Gly Asp 485 490 495 Arg Ala Gln Glu Ile Ala Gly Ser Ala Thr Val Lys Ile Gly Glu Lys 500 505 510 Val His Glu Ile Gly Ile Ala Gly Lys Gln Gly Ser Gly Gly Gly Gly 2013202593 05 Apr 2013 2013202593 05 Apr 2013 515 520 525 Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro 530 535 540 Leu Asp His Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser 545 550 555 560 Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys 565 570 575 Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp 580 585 590 Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln 595 600 605 Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His 610 615 620 Ser Ala Leu Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His 625 630 635 640 Ser Gly Lys Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala 645 650 655 Gly Glu His Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr 660 665 670 Tyr Arg Gly Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr 675 680 685 Tyr Thr Ile Asp Phe Ala Ala Lys Gln Gly Asn Gly Lys Ile Glu His 690 695 700 Leu Lys Ser Pro Glu Leu Asn Val Asp Leu Ala Ala Ala Asp Ile Lys 705 710 715 720 Pro Asp Gly Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn 725 730 735 Gln Ala Glu Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala 740 745 750 Gln Glu Val Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg 755 760 765 His Ile Gly Leu Ala Ala Lys Gln 770 775 <210> 18 <211> 686 <212> PRT <213> Neisseria meningitidis <400> 18 Met Val Ser Ala Val Ile Gly Ser Ala Ala Val Gly Ala Lys Ser Ala 1 5 10 15 Val Asp Arg Arg Thr Thr Gly Ala Gln Thr Asp Asp Asn Val Met Ala 20 25 30 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Leu Arg Ile Glu Thr Thr Ala Arg Ser Tyr Leu Arg Gln Asn Asn Gln 35 40 45 Thr Lys Gly Tyr Thr Pro Gln Ile Ser Val Val Gly Tyr Asp Arg His 50 55 60 Leu Leu Leu Leu Gly Gln Val Ala Thr Glu Gly Glu Lys Gln Phe Val 65 70 75 80 Gly Gln Ile Ala Arg Ser Glu Gln Ala Ala Glu Gly Val Tyr Asn Tyr 85 90 95 Ile Thr Val Ala Ser Leu Pro Arg Thr Ala Gly Asp Ile Ala Gly Asp 100 105 110 Thr Trp Asn Thr Ser Lys Val Arg Ala Thr Leu Leu Gly Ile Ser Pro 115 120 125 Ala Thr Arg Ala Arg Val Lys Ile Val Thr Tyr Gly Asn Val Thr Tyr 130 135 140 Val Met Gly Ile Leu Thr Pro Glu Glu Gln Ala Gln Ile Thr Gln Lys 145 150 155 160 Val Ser Thr Thr Val Gly Val Gln Lys Val Ile Thr Leu Tyr Gln Asn 165 170 175 Tyr Val Gln Arg Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly 180 185 190 Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys 195 200 205 Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys 210 215 220 Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp 225 230 235 240 Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp 245 250 255 Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser 260 265 270 Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe 275 280 285 Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys Met Val Ala 290 295 300 Lys Arg Gln Phe Arg Ile Gly Asp Leu Gly Gly Glu His Thr Ala Phe 305 310 315 320 Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr Arg Gly Thr Ala Phe Gly 325 330 335 Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Thr Lys 340 345 350 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser Pro Glu Leu Asn 355 360 365 Val Glu Leu Ala Ser Ala Glu Ile Lys Ala Asp Gly Lys Ser His Ala 370 375 380 Val Ile Leu Gly Asp Val Arg Tyr Gly Ser Glu Glu Lys Gly Ser Tyr 385 390 395 400 Ser Leu Gly Ile Phe Gly Gly Arg Ala Gln Glu Val Ala Gly Ser Ala 405 410 415 Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly Leu Ala Ala Lys 420 425 430 Gln Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly Ala Gly Leu 435 440 445 Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys Gly Leu Gln 450 455 460 Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys Leu Lys Leu 465 470 475 480 Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp Ser Leu Asn 485 490 495 Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp Phe Ile Arg 500 505 510 Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser Gly Glu Phe 515 520 525 Gln Val Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe Gln Thr Glu 530 535 540 Gln Ile Gln Asp Ser Glu His Ser Gly Lys Met Val Ala Lys Arg Gln 545 550 555 560 Phe Arg Ile Gly Asp Leu Gly Gly Glu His Thr Ala Phe Asn Gln Leu 565 570 575 Pro Asp Gly Lys Ala Glu Tyr Arg Gly Thr Ala Phe Gly Ser Asp Asp 580 585 590 Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Thr Lys Lys Gln Gly 595 600 605 Asn Gly Lys Ile Glu His Leu Lys Ser Pro Glu Leu Asn Val Glu Leu 610 615 620 Ala Ser Ala Glu Ile Lys Ala Asp Gly Lys Ser His Ala Val Ile Leu 625 630 635 640 Gly Asp Val Arg Tyr Gly Ser Glu Glu Lys Gly Ser Tyr Ser Leu Gly 645 650 655 Ile Phe Gly Gly Arg Ala Gln Glu Val Ala Gly Ser Ala Glu Val Lys 660 665 670 Thr Val Asn Gly Ile Arg His Ile Gly Leu Ala Ala Lys Gln 2013202593 05 Apr 2013 2013202593 05 Apr 2013 675 680 685 <210> 19 <211> 250 <212> PRT <213> Neisseria meningitidis <400>

19 Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro 1 5 10 15 Leu Asp His Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser 20 25 30 Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys 35 40 45 Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp 50 55 60 Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln 65 70 75 80 Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His 85 90 95 Ser Ala Leu Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His 100 105 110 Ser Gly Lys Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala 115 120 125 Gly Glu His Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr 130 135 140 Tyr Arg Gly Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr 145 150 155 160 Tyr Thr Ile Asp Phe Ala Ala Lys Gln Gly Asn Gly Arg Ile Glu His 165 170 175 Leu Lys Ser Pro Glu Leu Asn Val Glu Leu Ala Ser Ala Asp Ile Lys 180 185 190 Pro Asp Gly Lys Arg His Ala Val Ile Ser Gly Asp Val Arg Tyr Gly 195 200 205 Gly Glu Glu Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala 210 215 220 Gln Glu Val Ala Gly Ser Ala Glu Val Lys Ile Arg Asn Gly Ile Arg 225 230 235 240 His Ile Gly Leu Ala Ala Lys Gln Leu Glu 245 250 <210> 20 <211> 248 <212> PRT <213> Neisseria meningitidis 2013202593 05 Apr 2013 2013202593 05 Apr 2013 <400>

20 Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro 1 5 10 15 Leu Asp His Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser 20 25 30 Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys 35 40 45 Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp 50 55 60 Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln 65 70 75 80 Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His 85 90 95 Ser Ala Leu Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His 100 105 110 Thr Asp Lys Met Val Ala Lys Arg Gln Phe Arg Ile Ser Gly Ile Ala 115 120 125 Gly Glu His Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Lys Ala Glu 130 135 140 Tyr His Gly Lys Ala Phe Gly Ser Asp Asp Pro Asn Gly Arg Leu His 145 150 155 160 Tyr Thr Ile Asp Phe Ala Ala Lys Gln Gly Asn Gly Arg Ile Glu His 165 170 175 Leu Lys Ser Pro Glu Leu Asn Val Glu Leu Ala Ser Ala Asp Ile Lys 180 185 190 Pro Asp Gly Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn 195 200 205 Gln Ala Glu Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala 210 215 220 Gln Glu Val Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg 225 230 235 240 His Ile Gly Leu Ala Ala Lys Gln 245 <210> 21 <211> 248 <212> PRT <213> Neisseria meningitidis <400>

21 Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro 1 5 10 15 Leu Asp His Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser 20 25 30 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys 35 40 45 Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp 50 55 60 Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln 65 70 75 80 Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His 85 90 95 Ser Ala Leu Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His 100 105 110 Ile Asp Lys Met Val Ala Lys Arg Gln Phe Arg Ile Ser Gly Ile Ala 115 120 125 Gly Glu His Thr Ser Phe Asp Lys Leu Pro Glu Gly Gly Lys Ala Glu 130 135 140 Tyr His Gly Lys Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr 145 150 155 160 Tyr Thr Ile Asp Phe Ala Ala Lys Gln Gly His Gly Arg Ile Glu His 165 170 175 Leu Lys Ser Pro Glu Leu Asn Val Glu Leu Ala Ala Ala Asp Ile Lys 180 185 190 Pro Asp Gly Lys Arg His Ala Val Ile Ser Gly Ser Val Leu Tyr Asn 195 200 205 Gln Ala Glu Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala 210 215 220 Gln Glu Val Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg 225 230 235 240 His Ile Gly Leu Ala Ala Lys Gln 245 <210> 22 <211> 247 <212> PRT <213> Neisseria meningitidis <400>

22 Val Ala Ala Asp Ile Gly Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro 1 5 10 15 Leu Asp His Lys Asp Lys Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser 20 25 30 Val Arg Lys Asn Glu Lys Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys 35 40 45 Thr Tyr Gly Asn Gly Asp Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp 50 55 60 Lys Val Ser Arg Phe Asp Phe Ile Arg Gln Ile Glu Val Asp Gly Gln 2013202593 05 Apr 2013 2013202593 05 Apr 2013 65 70 75 80 Leu Ile Thr Leu Glu Ser Gly Glu Phe Gln Val Tyr Lys Gln Ser His 85 90 95 Ser Ala Leu Thr Ala Phe Gln Thr Glu Gln Ile Gln Asp Ser Glu His 100 105 110 Ser Gly Lys Met Val Ala Lys Arg Gln Phe Arg Ile Gly Asp Leu Gly 115 120 125 Gly Glu His Thr Ala Phe Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr 130 135 140 Arg Gly Thr Ala Phe Gly Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr 145 150 155 160 Thr Ile Asp Phe Thr Lys Lys Gln Gly Asn Gly Lys Ile Glu His Leu 165 170 175 Lys Ser Pro Glu Leu Asn Val Glu Leu Ala Ser Ala Glu Ile Lys Ala 180 185 190 Asp Gly Lys Ser His Ala Val Ile Leu Gly Asp Val Arg Tyr Gly Ser 195 200 205 Glu Glu Lys Gly Ser Tyr Ser Leu Gly Ile Phe Gly Gly Arg Ala Gln 210 215 220 Glu Val Ala Gly Ser Ala Glu Val Lys Thr Val Asn Gly Ile Arg His 225 230 235 240 Ile Gly Leu Ala Ala Lys Gln 245 <210> 23 <211> 179 <212> PRT <213> Neisseria meningitidis <400>

23 Val Ser Ala Val Ile Gly Ser Ala Ala Val Gly Ala Lys Ser Ala Val 1 5 10 15 Asp Arg Arg Thr Thr Gly Ala Gln Thr Asp Asp Asn Val Met Ala Leu 20 25 30 Arg Ile Glu Thr Thr Ala Arg Ser Tyr Leu Arg Gln Asn Asn Gln Thr 35 40 45 Lys Gly Tyr Thr Pro Gln Ile Ser Val Val Gly Tyr Asp Arg His Leu 50 55 60 Leu Leu Leu Gly Gln Val Ala Thr Glu Gly Glu Lys Gln Phe Val Gly 65 70 75 80 Gln Ile Ala Arg Ser Glu Gln Ala Ala Glu Gly Val Tyr Asn Tyr Ile 85 90 95 Thr Val Ala Ser Leu Pro Arg Thr Ala Gly Asp Ile Ala Gly Asp Thr 100 105 110 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Trp Asn Thr Ser Lys Val Arg Ala Thr Leu Leu Gly Ile Ser Pro Ala 115 120 125 Thr Arg Ala Arg Val Lys Ile Val Thr Tyr Gly Asn Val Thr Tyr Val 130 135 140 Met Gly Ile Leu Thr Pro Glu Glu Gln Ala Gln Ile Thr Gln Lys Val 145 150 155 160 Ser Thr Thr Val Gly Val Gln Lys Val Ile Thr Leu Tyr Gln Asn Tyr 165 170 175 Val Gln Arg <210> 24 <211> 686 <212> PRT <213> Neisseria meningitidis <400>

24 Met Val Ser Ala Val Ile Gly Ser Ala Ala Val Gly Ala Lys Ser Ala 1 5 10 15 Val Asp Arg Arg Thr Thr Gly Ala Gln Thr Asp Asp Asn Val Met Ala 20 25 30 Leu Arg Ile Glu Thr Thr Ala Arg Ser Tyr Leu Arg Gln Asn Asn Gln 35 40 45 Thr Lys Gly Tyr Thr Pro Gln Ile Ser Val Val Gly Tyr Asp Arg His 50 55 60 Leu Leu Leu Leu Gly Gln Val Ala Thr Glu Gly Glu Lys Gln Phe Val 65 70 75 80 Gly Gln Ile Ala Arg Ser Glu Gln Ala Ala Glu Gly Val Tyr Asn Tyr 85 90 95 Ile Thr Val Ala Ser Leu Pro Arg Thr Ala Gly Asp Ile Ala Gly Asp 100 105 110 Thr Trp Asn Thr Ser Lys Val Arg Ala Thr Leu Leu Gly Ile Ser Pro 115 120 125 Ala Thr Arg Ala Arg Val Lys Ile Val Thr Tyr Gly Asn Val Thr Tyr 130 135 140 Val Met Gly Ile Leu Thr Pro Glu Glu Gln Ala Gln Ile Thr Gln Lys 145 150 155 160 Val Ser Thr Thr Val Gly Val Gln Lys Val Ile Thr Leu Tyr Gln Asn 165 170 175 Tyr Val Gln Arg Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly 180 185 190 Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys 195 200 205 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys 210 215 220 Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp 225 230 235 240 Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp 245 250 255 Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser 260 265 270 Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe 275 280 285 Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys Met Val Ala 290 295 300 Lys Arg Gln Phe Arg Ile Gly Asp Leu Gly Gly Glu His Thr Ala Phe 305 310 315 320 Asn Gln Leu Pro Asp Gly Lys Ala Glu Tyr Arg Gly Thr Ala Phe Gly 325 330 335 Ser Asp Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Thr Lys 340 345 350 Lys Gln Gly Asn Gly Lys Ile Glu His Leu Lys Ser Pro Glu Leu Asn 355 360 365 Val Glu Leu Ala Ser Ala Glu Ile Lys Ala Asp Gly Lys Ser His Ala 370 375 380 Val Ile Leu Gly Asp Val Arg Tyr Gly Ser Glu Glu Lys Gly Ser Tyr 385 390 395 400 Ser Leu Gly Ile Phe Gly Gly Arg Ala Gln Glu Val Ala Gly Ser Ala 405 410 415 Glu Val Lys Thr Val Asn Gly Ile Arg His Ile Gly Leu Ala Ala Lys 420 425 430 Gln Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly Ala Gly Leu 435 440 445 Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys Gly Leu Gln 450 455 460 Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys Leu Lys Leu 465 470 475 480 Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp Ser Leu Asn 485 490 495 Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp Phe Ile Arg 500 505 510 Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser Gly Glu Phe 515 520 525 Gln Val Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe Gln Thr Glu 2013202593 05 Apr 2013 2013202593 05 Apr 2013 530 535 540 Gln Ile Gln Asp Ser Glu His Ser Gly Lys Met Val Ala Lys Arg Gln 545 550 555 560 Phe Arg Ile Gly Asp Leu Gly Gly Glu His Thr Ala Phe Asn Gln Leu 565 570 575 Pro Asp Gly Lys Ala Glu Tyr Arg Gly Thr Ala Phe Gly Ser Asp Asp 580 585 590 Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Thr Lys Lys Gln Gly 595 600 605 Asn Gly Lys Ile Glu His Leu Lys Ser Pro Glu Leu Asn Val Glu Leu 610 615 620 Ala Ser Ala Glu Ile Lys Ala Asp Gly Lys Ser His Ala Val Ile Leu 625 630 635 640 Gly Asp Val Arg Tyr Gly Ser Glu Glu Lys Gly Ser Tyr Ser Leu Gly 645 650 655 Ile Phe Gly Gly Arg Ala Gln Glu Val Ala Gly Ser Ala Glu Val Lys 660 665 670 Thr Val Asn Gly Ile Arg His Ile Gly Leu Ala Ala Lys Gln 675 680 685 <210> 25 <211> 687 <212> PRT <213> Neisseria meningitidis <400>

25 Met Val Ser Ala Val Ile Gly Ser Ala Ala Val Gly Ala Lys Ser Ala 1 5 10 15 Val Asp Arg Arg Thr Thr Gly Ala Gln Thr Asp Asp Asn Val Met Ala 20 25 30 Leu Arg Ile Glu Thr Thr Ala Arg Ser Tyr Leu Arg Gln Asn Asn Gln 35 40 45 Thr Lys Gly Tyr Thr Pro Gln Ile Ser Val Val Gly Tyr Asp Arg His 50 55 60 Leu Leu Leu Leu Gly Gln Val Ala Thr Glu Gly Glu Lys Gln Phe Val 65 70 75 80 Gly Gln Ile Ala Arg Ser Glu Gln Ala Ala Glu Gly Val Tyr Asn Tyr 85 90 95 Ile Thr Val Ala Ser Leu Pro Arg Thr Ala Gly Asp Ile Ala Gly Asp 100 105 110 Thr Trp Asn Thr Ser Lys Val Arg Ala Thr Leu Leu Gly Ile Ser Pro 115 120 125 Ala Thr Arg Ala Arg Val Lys Ile Val Thr Tyr Gly Asn Val Thr Tyr 130 135 140 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Val Met Gly Ile Leu Thr Pro Glu Glu Gln Ala Gln Ile Thr Gln Lys 145 150 155 160 Val Ser Thr Thr Val Gly Val Gln Lys Val Ile Thr Leu Tyr Gln Asn 165 170 175 Tyr Val Gln Arg Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly 180 185 190 Ala Gly Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys 195 200 205 Gly Leu Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys 210 215 220 Leu Lys Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp 225 230 235 240 Ser Leu Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp 245 250 255 Phe Ile Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser 260 265 270 Gly Glu Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe 275 280 285 Gln Thr Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys Met Val Ala 290 295 300 Lys Arg Gln Phe Arg Ile Gly Asp Ile Ala Gly Glu His Thr Ser Phe 305 310 315 320 Asp Lys Leu Pro Glu Gly Gly Arg Ala Thr Tyr His Gly Lys Ala Phe 325 330 335 Gly Ser Asp Asp Pro Asn Gly Arg Leu His Tyr Thr Ile Asp Phe Ala 340 345 350 Ala Lys Gln Gly Tyr Gly Arg Ile Glu His Leu Lys Thr Pro Glu Gln 355 360 365 Asn Val Asp Leu Ala Ala Ala Asp Ile Lys Pro Asp Gly Lys Arg His 370 375 380 Ala Val Ile Ser Gly Ser Val Leu Tyr Asn Gln Ala Glu Lys Gly Ser 385 390 395 400 Tyr Ser Leu Gly Ile Phe Gly Gly Lys Ala Gln Glu Val Ala Gly Ser 405 410 415 Ala Glu Val Lys Ile Gly Glu Gly Ile Arg His Ile Gly Leu Ala Ala 420 425 430 Lys Gln Gly Ser Gly Gly Gly Gly Val Ala Ala Asp Ile Gly Ala Gly 435 440 445 Leu Ala Asp Ala Leu Thr Ala Pro Leu Asp His Lys Asp Lys Gly Leu 450 455 460 2013202593 05 Apr 2013 2013202593 05 Apr 2013 Gln Ser Leu Thr Leu Asp Gln Ser Val Arg Lys Asn Glu Lys Leu Lys 465 470 475 480 Leu Ala Ala Gln Gly Ala Glu Lys Thr Tyr Gly Asn Gly Asp Ser Leu 485 490 495 Asn Thr Gly Lys Leu Lys Asn Asp Lys Val Ser Arg Phe Asp Phe Ile 500 505 510 Arg Gln Ile Glu Val Asp Gly Gln Leu Ile Thr Leu Glu Ser Gly Glu 515 520 525 Phe Gln Val Tyr Lys Gln Ser His Ser Ala Leu Thr Ala Phe Gln Thr 530 535 540 Glu Gln Ile Gln Asp Ser Glu His Ser Gly Lys Met Val Ala Lys Arg 545 550 555 560 Gln Phe Arg Ile Gly Asp Leu Gly Gly Glu His Thr Ala Phe Asn Gln 565 570 575 Leu Pro Asp Gly Lys Ala Glu Tyr Arg Gly Thr Ala Phe Gly Ser Asp 580 585 590 Asp Ala Gly Gly Lys Leu Thr Tyr Thr Ile Asp Phe Thr Lys Lys Gln 595 600 605 Gly Asn Gly Lys Ile Glu His Leu Lys Ser Pro Glu Leu Asn Val Glu 610 615 620 Leu Ala Ser Ala Glu Ile Lys Ala Asp Gly Lys Ser His Ala Val Ile 625 630 635 640 Leu Gly Asp Val Arg Tyr Gly Ser Glu Glu Lys Gly Ser Tyr Ser Leu 645 650 655 Gly Ile Phe Gly Gly Arg Ala Gln Glu Val Ala Gly Ser Ala Glu Val 660 665 670 Lys Thr Val Asn Gly Ile Arg His Ile Gly Leu Ala Ala Lys Gln 675 680 685 <210> 26 <211> 226 <212> PRT <213> Neisseria meningitidis <400>

26 Met Glu Asn Ile Thr Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln 1 5 10 15 Ala Gly Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser Leu 20 25 30 Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly Gly Ser Pro Val Cys 35 40 45 Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn His Ser Pro Thr Ser 50 55 60 Cys Pro Pro Ile Cys Pro Gly Tyr Arg Trp Met Cys Leu Arg Arg Phe 2013202593 05 Apr 2013 2013202593 05 Apr 2013 65 70 75 80 Ile Ile Phe Leu Phe Ile Leu Leu Leu Cys Leu Ile Phe Leu Leu Val 85 90 95 Leu Leu Asp Tyr Gln Gly Met Leu Pro Val Cys Pro Leu Ile Pro Gly 100 105 110 Ser Thr Thr Thr Asn Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro Ala 115 120 125 Gln Gly Asn Ser Met Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr Asp 130 135 140 Gly Asn Cys Thr Cys Ile Pro Ile Pro Ser Ser Trp Ala Phe Ala Lys 145 150 155 160 Tyr Leu Trp Glu Trp Ala Ser Val Arg Phe Ser Trp Leu Ser Leu Leu 165 170 175 Val Pro Phe Val Gln Trp Phe Val Gly Leu Ser Pro Thr Val Trp Leu 180 185 190 Ser Ala Ile Trp Met Met Trp Tyr Trp Gly Pro Ser Leu Tyr Ser Ile 195 200 205 Val Ser Pro Phe Ile Pro Leu Leu Pro Ile Phe Phe Cys Leu Trp Val 210 215 220 Tyr Ile 225 <210> 27 <211> 1060 <212> DNA <213> Neisseria meningitidis <400> 27 aagcttacca gttctcacac ggaacaccac taatggacac acattcgaaa tactttgacc 60 ctattttcga ggaccttgtc accttgagcc caagagagcc aagatttaaa ttttcctatg 120 acttgatgca aattcccaaa gctaataaca tgcaagacac gtacggtcaa gaagacatat 180 ttgacctctt aacaggttca gacgcgactg cctcatcagt aagacccgtt gaaaagaact 240 tacctgaaaa aaacgaatat atactagcgt tgaatgttag cgtcaacaac aagaagttta 300 ctgacgcgga ggccaaggca aaaagattcc ttgattacgt aagggagtta gaatcatttt 360 gaataaaaaa cacgcttttt cagttcgagt ttatcattat caatactgcc atttcaaaga 420 atacgtaaat aattaatagt agtgattttc ctaactttat ttagtcaaaa aattagcctt 480 ttaattctgc tgtaacccgt acatgcccaa aatagggggc gggttacaca gaatatataa 540 catcgtaggt gtctgggtga acagtttatt cctggcatcc actaaatata atggagcccg 600 ctttttaagc tggcatccag aaaaaaaaag aatcccagca ccaaaatatt gttttcttca 660 ccaaccatca gttcataggt ccattctctt agcgcaacta cagagaacag gggcacaaac 720 aggcaaaaaa cgggcacaac ctcaatggag tgatgcaacc tgcctggagt aaatgatgac 780 acaaggcaat tgacccacgc atgtatctat ctcattttct tacaccttct attaccttct 840 gctctctctg atttggaaaa agctgaaaaa aaaggttgaa accagttccc tgaaattatt 900 cccctacttg actaataagt atataaagac ggtaggtatt gattgtaatt ctgtaaatct 960 atttcttaaa cttcttaaat tctactttta tagttagtct tttttttagt tttaaaacac 1020 caagaactta gtttcgaata aacacacata aacaaacaaa 1060 <210> 28 <211> 1063 <212> DNA <213> Neisseria meningitidis 2013202593 05 Apr 2013 2013202593 05 Apr 2013 <400> 28 aagcttacca gttctcacac ggaacaccac taatggacac acattcgaaa tactttgacc 60 ctattttcga ggaccttgtc accttgagcc caagagagcc aagatttaaa ttttcctatg 120 acttgatgca aattcccaaa gctaataaca tgcaagacac gtacggtcaa gaagacatat 180 ttgacctctt aacaggttca gacgcgactg cctcatcagt aagacccgtt gaaaagaact 240 tacctgaaaa aaacgaatat atactagcgt tgaatgttag cgtcaacaac aagaagttta 300 ctgacgcgga ggccaaggca aaaagattcc ttgattacgt aagggagtta gaatcatttt 360 gaataaaaaa cacgcttttt cagttcgagt ttatcattat caatactgcc atttcaaaga 420 atacgtaaat aattaatagt agtgattttc ctaactttat ttagtcaaaa aattagcctt 480 ttaattctgc tgtaacccgt acatgcccaa aatagggggc gggttacaca gaatatataa 540 catcgtaggt gtctgggtga acagtttatt cctggcatcc actaaatata atggagcccg 600 ctttttaagc tggcatccag aaaaaaaaag aatcccagca ccaaaatatt gttttcttca 660 ccaaccatca gttcataggt ccattctctt agcgcaacta cagagaacag gggcacaaac 720 aggcaaaaaa cgggcacaac ctcaatggag tgatgcaacc tgcctggagt aaatgatgac 780 acaaggcaat tgacccacgc atgtatctat ctcattttct tacaccttct attaccttct 840 gctctctctg atttggaaaa agctgaaaaa aaaggttgaa accagttccc tgaaattatt 900 cccctacttg actaataagt atataaagac ggtaggtatt gattgtaatt ctgtaaatct 960 atttcttaaa cttcttaaat tctactttta tagttagtct tttttttagt tttaaaacac 1020 caagaactta gtttcgaata aacacacata aacaaacaaa atg 1063 2013202593 05 Apr 2013 2013202593 05 Apr 2013